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Across the globe and in Singapore, ovarian cancer remains the most deadly of the 
gynaecological cancers and now surpasses cervical cancer in prevalence. Although, 
patients suffering from ovarian cancer respond well to the first line platinum-based 
chemotherapy, majority of them relapse within a relatively short period of time.  
Presently, there are limited chemotherapy options to treat platinum resistant ovarian 
cancer.  Thus, there is a need to develop novel treatment regimen that can be useful for 
patients suffering from platinum resistant ovarian cancer.  Recent clinical trial data have 
suggested that the combination of doxorubicin and irinotecan may be synergistic when 
administered together in the treatment of platinum resistant ovarian carcinoma.  With 
well known ability to reduce the adverse side effects of the encapsulated drug and deliver 
the drugs to the target tumor site, it is hypothesized that liposomes co-encapsulating 
doxorubicin and irinotecan in a synergistic ratio would be an appropriate drug delivery 
system to treat ovarian cancer effectively.  The present thesis presents a systematic 
approach to the design of such co-encapsulated liposomes. 
In order to get maximum benefit from combination therapy, it is essential that the 
drugs are delivered in fixed synergistic ratio to the tumor cells.  Results from section 4.1 
have revealed that 1:1 ratio of doxorubicin: irinotecan was the most synergistic ratio in all 
the three ovarian cancer cell lines (OVCAR-3, SKOV3 and IGROV-1) when analyzed 
using MTT assay.  While the synergistic ratio 1:1 of the two drugs was found effective in 
vitro, it is essential that these two drugs are delivered in vivo in the same ratio so that the 
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tumor site is equally co-exposed to both the drugs. The results in section 4.2 
demonstrated that MnSO4 plus ionophore A23187 DSPC/cholesterol based liposomal 
preparations not only offered 100% encapsulation for both the drugs but also provided 
the much desired synchronized release pattern over a study period of 72h.  In addition, no 
significant change in size, polydispersity and drug content was observed over a storage 
period of 6 months at 2-8 ºC.  From formulation perspective a liposomal preparation with 
high drug payload is always an advantage.  The results in section 4.2 showed that there is 
direct correlation between intraliposomal manganese concentration and the amount of 
drug that can be loaded into the liposome and maximum of 0.9:1 drug to lipid molar ratio 
can be efficiently loaded using 750 mM of MnSO4 , a finding which is by far unique to 
this study.  For any formulation to be transformed from lab to bench, it is important to 
evaluate its in vivo performance. The results in section 4.4 demonstrated that 
pharmacokinetic profiles of doxorubicin and irinotecan were improved as compared to 
free drugs when co-encapsulated into the liposomes.  In addition, the formulation 
exhibited significant antitumour activity at two-thirds of the maximum tolerated dose of 
doxorubicin and one tenth of that of irinotecan in an IGROV-1 tumor bearing mice 
model.  The results from these studies warrant further testing of this liposome 
formulation in clinical settings.  The success of this project may provide a better 
alternative to the current treatments for the refractory type of ovarian cancer, and may 
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1.1 Ovarian Cancer: Overview  
 
The World Health Organization (WHO) defines cancer as a generic term for a 
large group of diseases that can affect any part of the body.  One defining feature of 
cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, 
and which can then invade adjoining parts of the body and spread to other organs, a 
process referred to as metastasis.  As per WHO, cancer is a leading cause of death 
worldwide and it accounted for 7.9 million deaths (around 13% of all deaths) in 2007.  
In addition, deaths from cancer worldwide are projected to rise, with an estimated 12 
million deaths by 2030 (WHO, Global cancer statistics 2007).  Cancer can be 
classified into several main types based on the organ from which they originate.  
Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal 
organs.  Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, 
or other connective or supportive tissue.  Leukemia is a cancer that starts in blood-
forming tissue such as the bone marrow, and causes large numbers of abnormal blood 
cells to be produced and enter the blood. Lymphoma and multiple myeloma are 
cancers that begin in the cells of the immune system. Central nervous system cancers 
are cancers that begin in the tissues of the brain and spinal cord (National Cancer 
Centre, US).  The other common way of classifying cancer is according to the organ 
affected, such as breast cancer, lung cancer, blood cancer, ovarian cancer and many 
others.  Of all cancers, related to female reproductive system, ovarian cancer accounts 
for the greatest number of deaths in women across the globe.  Moreover, ovarian 
cancer is the fifth most common cancer among women in Singapore and worldwide 
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(National Cancer Centre, US) (Table 1).  A steady increase in the cases of ovarian 
cancer has been observed in Singapore over the past three decades, and it now 
surpasses cervical cancer in terms of prevalence (Pang 2010).  As per Singapore 
Cancer Registry Interim Report 2003-2007, there are about 265 new cases of ovarian 
cancer diagnosed every year and close to 100 women die from it.  National Cancer 
Institute (NCI) defines ovarian cancer as carcinoma that forms in tissues of the ovary 
(one of a pair of female reproductive glands in which the ova, or eggs, are formed).  
The exact cause of ovarian cancer is unknown, although there are some possible risk 
factors such as obesity, family history of ovarian cancer, use of fertility drugs, 
smoking, which are considered to cause ovarian cancer (Sarantaus, Vahteristo et al. 
2001; Rossing, Tang et al. 2004).  There are 3 main types of ovarian cancer; namely 
epithelial, germ cell and sex cord stromal ovarian cancer; the most common type is 
epithelial ovarian cancer that arise from cells that line or cover the ovaries (Scully 
1977).  The four different stages of ovarian cancer include: Stage I, where the 
cancerous cells are confined to one or both ovaries; Stage II, where the cancerous 
cells have spread to the uterus or other nearby organs; Stage III, where the cancerous 
cells has spread to the lymph nodes or abdominal lining, and finally Stage IV, is 
where they spread to distant organs, such as the lungs or liver is evident (Heintz, 
Odicino et al. 2006).  The most dangerous aspect of ovarian cancer is its late 
diagnosis, a stage where life expectancy is already very small.  Unfortunately, a lack 
of early symptoms and deficiency of effective screening tests have resulted in delayed 
diagnosis of ovarian cancer in advance stage when the cancer has spread beyond the 
ovary (Urban and Drescher 2008).   Presently, two diagnostic tests are often used for 
the detection of ovarian cancer, namely transvaginal sonography and cancer antigen 
125 (CA-125) test (Meldrum, Chetkowski et al. 1984; Bast, Xu et al. 1998).  
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Transvaginal sonography is the test that is performed by placing a small probe called 
transducer across the vagina where an image is generated with the help of transducer 
on a computer screen.  This method is intended to locate a tumor mass on the ovary (if 
any).  However, this method has found to be ineffective in detecting ovarian cancer in 
which ovarian volume is normal and tumor mass is small (Hudelist, Ballard  et al. 
2011).  CA-125 is a protein/antigen in the blood and is used as biomarker in detection 
of ovarian cancer.  However, CA-125 is found to be non-specific biomarker for 
ovarian cancer as high levels of CA-125 has also been reported for cancers originating 
from endometrium, fallopian tubes, lungs, breast and gastrointestinal tract (Bast, 
Badgwell et al. 2005; Rosen, Wang et al. 2005).  The other concern for management 
of ovarian cancer is related to use of appropriate chemotherapy regimen.  
Development of resistance towards commonly used drugs for the treatment of ovarian 
cancer has been a major concern (Ozols 2006). 
Ovarian cancer is a very painful reality for women.  It is reported that if the 
ovarian cancer is detected in its early stage, when the tumor is still confined to the 
ovary and if treated with appropriate anticancer drugs or drug combinations the long 
term survival rate of patients is around 92%.  On the other hand, when the tumor 
spreads beyond the ovary, the long term survival rate of the patient reduces 
dramatically to 20-25% (Heintz, Odicino et al. 2006).  Thus, accurate methods for 
detecting specifically ovarian cancer and novel anticancer drugs or drug combinations 
for treating ovarian cancer are required, so as to screen women for ovarian cancer at 
its early stage and treat it with suitable chemotherapy regimen.  The development of 
new, effective and specific screening techniques for detection of ovarian cancer is 
beyond the scope of this thesis.  The present thesis mainly deals with the treatment of 
ovarian cancer, in particular the development of novel chemotherapeutic regimen. 
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 The success of this work will add to the current regimen of chemotherapy of 
ovarian cancer and will play its part in effective management of ovarian carcinoma, in 
general.  Details about current treatment modalities employed in managing ovarian 
cancer and novel antitumor compounds that has shown promise to overcome the 
problem of drug resistance in treatment of ovarian cancer are discussed in the next 
section. 
Table 1: Top 10 Cancers affecting women in Singapore, Source: Singapore Cancer Registry Interim 
Report 2004-2008. 
Rank Site affected Number 
1 Breast 7160 
2 Colo-rectum 3579 
3 Lung 1948 
4 Corpus Uteri 1434 
5 Ovary 1403 
6 Lymphoid Neoplasms 1012 
7 Cervix Uteri 1001 
8 Skin (including melanoma) 941 
9 Stomach 932 





1.2 Treatments for ovarian cancer 
The treatment for ovarian cancer mainly includes laparotomy, radiotherapy 
and chemotherapy (Hensley 2002; Martin 2007).  Laparatomy involves a surgery in 
which the affected ovaries, fallopian tubes, uterus and the surrounding organs are 
removed depending on the condition of the tumor and stage of cancer.  In addition to 
being a form of treatment, surgery is also used to diagnose ovarian cancer and 
determine its stage.  Radiotherapy is the use of radiation to kill tumor cells.  It is 
occasionally used, especially if the tumor is confined to the pelvis.  Chemotherapy 
involves the use of anticancer drugs to destroy and stop cancer cells from multiplying.  
Chemotherapy is employed mostly following surgery or when the tumor has 
reoccurred. Drugs can be delivered as injections intravenously, intraperitnoeally, and 
intramuscularly or administered orally. However, the most popular routes of 
administration in treatment of ovarian cancer are intravenous and intraperitnoeal.  
Among the various chemotherapeutic agents available, platinum-based drugs such as 
carboplatin or cisplatin and taxane compounds such as paclitaxel are the first-line 
drugs used in treatment of ovarian cancer (Ozols 2003; Vasey, Jayson et al. 2004).  
Although the initial response rate with platinum containing drugs is approximately 
70% to 80%, the majority of patients relapse within relatively short period of time 
(Ozols 2006).  Patients with platinum-sensitive tumors can be re-treated with platinum 
and/or paclitaxel, and those who have developed resistance to these drugs need to be 
treated with alternative drugs.  Agents that have emerged as useful alternative 
treatment options for platinum-resistant ovarian cancer include topoisomerase 
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inhibitors (Luce, Dow et al. 2003; Ozols 2006).  Topoisomerase inhibitors are a class 
of drugs that act by inhibiting the normal activity of topoisomerases and have gained a 
wide interest as antitumor agents in the past decade.  A detailed description about 
topoisomerase and its inhibitors is provided in the following section. 
 
1.3 DNA topoisomerase enzymes and topoisomerase inhibitors  
DNA topoisomerase are enzymes involved in the unknotting of DNA 
molecules by creating transient breaks in the DNA using a conserved tyrosine as the 
catalytic residue (Champoux 1990; Osheroff 1998).  They were first discovered in 
1971 (Holden 2001).  They change the topology, or three-dimensional geometry, of 
DNA molecules without changing their underlying chemical structure, thus the name, 
topoisomerase (Wang 2002).  Topoisomerase enzyme can be mainly divided in to two 
classes based on their reaction mechanism-type I and type II.   The type I topoisomerase 
catalyzes reactions that cause transient single strand DNA breaks, whereas the type II 
topoisomerase acts by making transient double strand DNA breaks.  Human cells contain 
one type I and two type II topoisomerases (Zhang, Barcélo et al. 2001).  Both of these 
topoisomerase enzymes are essential for DNA replication, RNA transcription, 
chromosomal condensation and mitotic chromatid separation, and thus have a vital 
role to play in cell growth.  Due to the multifunctional nature of the DNA 
topoisomerase in cell growth, they have also proven to be effective drug targets in the 
treatment of cancer.  Several anticancer drugs have been reported to inhibit 
topoisomerase activity and are used to treat a variety of hematologic and solid 
malignancies (Salerno, Da Settimo et al. 2010).   These anticancer drugs are known as 
topoisomerase inhibitors. Based on the type of topoisomerase enzyme they inhibit, 
they can be further classified as topoisomerase inhibitor I or topoisomerase inhibitor II 
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(Capranico, Zunino 1992; Holden 2001).  These drugs act by covalently binding to 
DNA-topoisomerase I/II cleavable complex; this binding still permits the normal 
unwinding of the double stranded DNA but prevents its subsequent relegating step, thus 
causing DNA cleavage and eventual cell death.   
Preclinical and clinical studies have indicated that topoisomerase inhibitors could 
be used either as single agent (topoisomerase inhibitor I or topoisomerase inhibitor II) 
or in combination (topoisomerase inhibitor I plus topoisomerase inhibitor II) for 
treatment of various types of cancers (Salerno, Da Settimo et al. 2010).  Camptothecin 
derivatives such as irinotecan, 9-aminocamptothecin (9-AC) and topotecan are 
examples of topoisomerase I inhibitors that have demonstrated antitumor activities 
(Rothenberg 1997). Actinomycin D, adriamycin and daunorubicin, elliptinium 
acetate, mitoxantrone, etoposide and teniposide, amsacrine are examples of 
topoisomerase II inhibitors that exhibit antitumor activities (Capranico, Giaccone et 
al. 1997).  Despite their useful antitumor effects, the use of topoisomerase inhibitors 
as single agent suffers from two main disadvantages; i.e. emergence of secondary 
malignancies and development of drug-resistant tumor cells (Felix 1998; Mistry, Felix 
et al. 2005; Azarova, Lyu et al. 2007; Saraiya, Gounder et al. 2008).  Topoisomerase 
II inhibitors when used alone have been reported to induce chromosomal translocation 
leading to secondary leukemia (Felix 1998; Mistry, Felix et al. 2005; Azarova, Lyu et 
al. 2007).  Emergence of drug-resistant tumor cells have been reported when 
topoisomerase I inhibitors are used as single agent (Saraiya, Gounder et al. 2008).  To 
overcome these issues, use of combination chemotherapy of topoisomerase I inhibitor 
plus topoisomerase II has been suggested (Salerno, Da Settimo et al. 2010).  
Examples of drug cocktails containing both topoisomerase I/II inhibitors include 
Irinotecan/Etoposide, Topotecan/Mitoxantrone, Topotecan/Doxorubicin, and 
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Irinotecan/Doxorubicin (Houghton, Cheshire et al. 1996; McCarley, Sheilachu 2001; 
Tolcher, Shaughnessy 1997; Krauze, Noble et al. 2007).  In particular, the 
combination of irinotecan/doxorubicin has shown great promise as antitumor drug 
cocktail in the past few years.  Nishimura et al. conducted a Phase II clinical trial to 
evaluate the efficacy of irinotecan/doxorubicin in the treatment of early recurrent or 
platinum refractory ovarian cancer.  The outcome of the studies suggested that this 
combination regimen was more effective than for treatment of platinum refractory 
ovarian cancer patients, when compared to treating with irinotecan alone (Nishimura, 
Tsuda et al. 2007).  Krauze et al. have reported that the combination of 
irinotecan/doxorubicin is a useful drug combination in the treatment of brain tumors 
as shown in a rodent intracranial brain tumor xenograft model (Krauze, Noble et al. 
2007).   Morgensztern et al. has carried out a Phase I study on patients suffering from 
solid tumors to evaluate the potential of irinotecan/doxorubicin combination in 
treatment of various solid tumors.  The results of this study suggested that 
irinotecan/doxorubicin combination has great potential in treating solid tumors and 
this regimen was suggested to be further studied in patients with tumors known to 
have sensitivity to both topoisomerase I and II inhibitors such as small-cell lung 
cancer or ovarian cancer (Morgensztern, Baggstrom et al. 2009).  Recently, a Phase II 
trial has demonstrated that the combination of irinotecan/doxorubicin was well 
tolerated among patients and had good activity in treatment of refractory type of 
small-cell lung cancer (Xenidis, Vardakis et al. 2010).  Considering the promising 
antitumor activities displayed by the irinotecan/doxorubicin drug combination in 
treatment of various types of cancer, particularly refractory type of ovarian cancer, we 
adopted this drug combination in the current research project so as to further explore 
the potential of this drug combination for treatment of ovarian cancer in tumor mouse 
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model.  A detailed description of the physicochemical and biological properties of 
these two drugs is given as follows. 
Irinotecan hydrochloride trihydrate (Figure1) is a semi-synthetic derivative of 
camptothecin and is also known as CPT-11.  Camptothecin belongs to a group of 
chemicals called alkaloids, and is extracted from plants such as Camptotheca 
acuminate.   Irinotecan is a prodrug designed to deliver the poorly soluble parent 
molecule SN-38.   Irinotecan is converted in vivo into its active metabolite (SN-38) by 
the enzyme carboxylesterase (CES).  SN-38 binds DNA-topoisomerase I covalently to 
form DNA-SN38-topoisomerase cleavable complex, resulting in DNA strand 
breakage and subsequent cell injury and death (Ahmed, Vyas et al. 1999, Guichard, 
Terret et al. 1999).  The cytotoxic action of SN-38 is likely to take place during S-
phase of cell growth.  The major side effect reported with the use of irinotecan 
includes diarrhea and myelosupression (Rothenberg 2001).  Irinotecan is available 
under the trade name Camptosar® and is primarily used to treat colon or rectal cancer. 
In addition it is recommended as second line treatment in ovarian carcinoma 
(Rothenberg 2001). 
 
Figure 1: Chemical structure of irinotecan hydrochloride trihydrate 
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Doxorubicin HCL (Figure 2) is a cytotoxic anthracycline antibiotic isolated 
from cultures of Streptomyces peucetius var. caesius (Sullivan, Latham et al. 1987).  
Doxorubicin inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase 
II cleavable complexes, preventing the DNA relegation process that is catalyzed by 
topoisomerase II during the DNA synthesis (Sullivan, Latham et al. 1987).  In 
addition to inhibiting topoisomerase II, the cytotoxic effects of doxorubicin are also 
thought to be related to nucleotide base intercalation.  Intercalation inhibits nucleotide 
replication and the action of DNA and RNA polymerases, leading to decreased 
macromolecular biosynthesis and subsequent cell death.  Doxorubicin is 
commercially available in hydrochloride salt form as saline based injections under the 
trade name Adriamycin®.  It is approved for treatment of acute leukemia, wilmis 
tumour, neuroblastoma, soft tissue sarcomas, breast carcinoma, hodgkin's and non-
hodgkin's lymphoma, bronchogenic carcinoma, hepatoma, and ovarian carcinoma 
(Sullivan, Latham et al. 1987).  Apart from conventional saline based injections, 
doxorubicin is also commercially available as liposome based injections under 
different trade names (Doxil ®, Mycocet ®, Evacet ®, and Caelyx®).  The major side 
effects associated with the use of doxorubicin includes cardiotoxicity, alopecia (hair 
loss), nausea and leucopoenia. 
 
Figure 2: Chemical structure of doxorubicin HCl 
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Cancer involves multiple signal transduction pathways and inhibiting one 
particular signaling pathway or any one growth factor receptor has modest effect. 
Drug combination often results in therapeutic efficacy greater than that achieved by 
use of single drug.  This is also evident in the above examples, where combination of 
topoisomerase inhibitor I with topoisomerase II inhibitor was found to be more 
efficacious than the individual topoisomerase inhibitor I/ II based drugs. This 
enhanced effect of drug combination could be attributed to the ability of drug 
combinations to target multiple signaling/survival pathways.  In order to get desired 
efficacy with minimum toxicity from drug combinations, it is important that the drug 
combinations are designed with appropriate rational. The various approaches dealing 
with drug combinations design in cancer treatment are discussed in the next section. 
 
1.4 Rational design of anticancer drug combinations  
The concept of drug combination was first founded by Frei and co-workers in 
1965 (Frei 1991).  They proposed the principles for selecting cytotoxic drugs to make 
up the anticancer drug cocktail.  These principles include a) the use of two drugs with 
different mechanisms of action with the purpose of reducing the development of 
possible broad spectrum drug resistance, b) the use of two or more drugs with an aim 
of delivering each drug in the combination regimen at near maximal tolerated dose 
(MTD) so as to achieve maximum tumor cell killing in patients (Frei 1991; DeVita 
1997).  In this MTD approach, combination chemotherapy regimens were developed 
by escalating the doses of individual agents to maximum tolerated dose.   This 
approach is based on conventional wisdom that ‘more-is-better’ and therefore 
exposure of more drugs to the tumor cells might lead to greater efficacy, which may 
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not always be true.  In fact, the clinical data has suggested that this approach often 
results in serious toxicity issues rather than superior efficacy (Delbaldo, Michiels et 
al. 2004; Breathnach, Freidlin et al. 2001; Mayer, Harasym et al. 2006).    Because of 
unwanted toxicities of MTD approach, alternative strategy in combination 
chemotherapy dose optimization has been long suggested. 
Recent reported studies state that the therapeutic effect of drug combination is 
often dependant on the molar ratio of the individual drugs used in the regimen, 
whereby synergistic, additive or antagonistic effects are observed when tumors are 
exposed to synergistic, additive or antagonistic molar drug ratios (Mayer, Harasym et 
al. 2006; Tardi, Dos Santos et al. 2009).  Synergism refers to the effect where two 
drugs in combination produce greater effect than that achieved with either drug alone 
under identical treatment condition.  Additivity refers to the effect where two drugs 
used in combination produce an effect that is sum of the effects of individual agents.  
Antagonism refers to the effect where two drugs used in combination produce an 
effect that is less than that achieved with either drug alone (Chou, and Talalay 1984).  
Thus, considering the profound effects that molar ratios of the individual drugs 
incorporated in the drug combinations could have on the therapeutic outcome of 
combination chemotherapy, it is of prime importance first to identify whether the 
employed drug combination will lead to synergistic, additive or antagonistic effect.  
Several mathematical models have been developed to determine synergistic, additive 
or antagonistic effect in the drug combinations, and the two most widely used models 
are isobologram method (Berenbaum 1985; Berenbaum 1989) and the median-effect 
principle (Chou and Talalay 1984).  The isobologram method allows the evaluation of 
a drug combination at a fixed effect level, but the analysis is only accurate for drugs 
with similar mechanism of action.  The advantage of isobologram method is that it is 
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easy to plot, and synergism, additivity and antagonism can be easily visualized from 
the graph (Figure 3).  However, it suffers from the disadvantage that it requires large 
amount of data to carry out analysis of single and drug combination effects.  
Moreover, the isobologram method fails to quantify the extent of synergism and 
antagonism.  The median-effect principle by Chou and Talalay allows the analysis of 
dose-effect relationships with single and multiple drugs, which can then be used to 
determine the drug interaction (Chou, and Talalay 1984).  Unlike isobologram 
method, the median effect principle can be used to determine drug interaction in fixed 
as well as non-fixed ratio.  The median-effect principle is the most popular method, 
with the original publication by Chou and Talalay receiving more than 900 citations.   
According to Chou and Talalay, the median effect equation states that 
fa/fu = (D/Dm) m     ….        Equation 1 
D = Dm[ fa / (1 – fa)]1/m 
The above equation is linearized by taking logarithms, 
Log fa/fu = m log (D) – m log Dm and plotted as median effect plot. 
where Fa= the fraction affected by the dose, Fu= the fraction unaffected 
(where Fu = 1- Fa), D= dose of the drug, Dm = median dose indicating potency, m = 
an exponent representing the shape of the dose effect curve and signifies the 
sigmoidicity of the dose effect curve, which is determined by the slope of the median-





In order to obtain quantitative determination of drug interaction, combination 
index (CI) equation was derived from equation 1: 
CI= [(D) 1/ (Dx)1]+ [(D) 2/ (Dx)2]+ [(D) 1 (D)2]/ [(Dx) 1/ (Dx)2] ….   Equation 2 
CI is a measure of the synergy/additive or antagonistic effect.  A drug 
combination is synergistic if its CI value is below or equal to 0.9; the combination is 
additive where the CI is between 0.9 and 1.1; and the combination is antagonistic as 
indicated by CI values above 1.1 (Figure 3) (Chou, and Talalay 1984).   
This median-effect principle technique can also be adapted for cell-based 
screening assays. Moreover, this method has good biological relevance and the in 
vitro results generated using cell-based screening assays have been shown to correlate 
well with the in vivo results generated during animal studies (Abraham, McKenzie et 
al. 2004; Mayer and Janoff 2007; Tardi, Johnstone et al. 2009).  In view of the 
advantages, the evaluations of selected drug combinations presented in this thesis will 
be analyzed by the median-effect principle.  Although the concentration and duration 
of administered drugs can be tightly controlled in vitro, it is a difficult task to translate 
these ratios in vivo due to the different pharmacokinetic profile of each drug in the 
combination.  This results in drug ratios in circulation that are different from those 
observed and optimized using cell culture based techniques and are potentially 
antagonistic at the site of action.  One of the techniques to overcome this issue is to 
make use of nanoparticulate drug delivery systems which could a) effectively co-
encapsulate the two anticancer drugs that needs to be added in drug combination 
regimen b) maintain the synergistic/additive ratio of the two anticancer drugs when 
delivering to the site of action, and c) coordinate the release of the two anticancer 
drugs at the synergistic/additive ratio at the site of action (Mayer and Janoff 2007).  In 
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the next section, a brief overview of nanoparticulate drug delivery systems in the 





Figure 3: (A) Schematic representation of isobologram for drugs A and B. (Figure adapted 
from Chou 2010). (B) Representative Fa-CI plot generated with the help of MEP method of 




1.5  Nanoparticulate drug delivery systems in cancer therapeutics 
In the treatment of cancer, it is desired that the drugs administered are 
distributed specifically to the cancerous cells and not in the normal cells.  
Unfortunately, conventional chemotherapeutic agents used in cancer treatment are 
distributed non-specifically in the body, affecting both cancerous and normal cells, 
thereby resulting in accumulation of sub-optimal dose in the cancerous cells and 
causing excessive toxicity to the normal body tissues. On the other hand, 
nanoparticulate drug delivery systems, by using both passive and active targeting, can 
result in increased amount of drug concentration in the cancer cells and decreased 
drug exposure to the normal tissues (Maeda 2001; Allen 2002).   Passive targeting of 
nanoparticles is mainly related to enhanced permeation and retention (EPR) effect 
(Matsumura and Maeda 1986).  Rapid growth of  tumor cells results in development 
of new blood vessels (neovascularization) or diversion of existing blood vessels to the 
tumor mass to supply them with oxygen and nutrients (Carmeliet and Jain 2000).  The 
resulting imbalance of angiogenic regulators such as growth factors and 
metalloproteinase makes tumor vessels highly porous and thereby increasing vascular 
permeability.  Furthermore, the lack of functional lymphatic system in tumor cells 
results in poor drainage of foreign particles and thereby increasing the retention of 
nanoparticles.  These unique pathological features are observed only in tumor cells 
and are collectively called as EPR effect; it constitutes an important mechanism by 
which nanoparticles can selectively accumulate in tumor interstitium (Matsumura and 
Maeda 1986; Carmeliet and Jain 2000).  Active targeting of nanoparticles involves 
inclusion of ligand or antibody to the nanoparticles (Tolcher, Sugarman 1999; 
Leamon and Reddy 2004).  The use of active targeting with nanoparticles allows 
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specific delivery of the drugs to the site of action and reduces adverse side effects 
(Allen 2002).   
Nanoparticulate drug delivery systems have shown great promise in the 
treatment of cancer and thus have gained a lot of interest in the past decade in cancer 
therapeutics.  Nanoparticulate drug delivery systems include formulations in the 
submicron range (Park, Lee et al. 2008).  These nanoparticles are made up of a variety 
of materials such as polymers (polymeric nanoparticle, micelles, or dendrimers), 
lipids (liposomes), viruses (viral nanoparticles), and organometalic compound (carbon 
nanotubes) (Figure 4).  Table 2 provides description of various nanoparticle based 
drug delivery systems along with selected examples (Cho, Wang et al. 2008).  Among 
the products discussed in Table 2, liposomal drugs and polymer-drug conjugates are 
the two most dominant classes and account for more than 80 % of the clinically 
approved nanoparticle based drug delivery systems (Zhang, Gu et al. 2008).  Polymer-
drug conjugates have been found to be effective in delivering anticancer compounds 
and around fourteen polymer-drug conjugate based products are under clinical 
development.  However, despite success in cancer treatment as carrier, polymer-drug 
conjugates have certain drawbacks, which include limited availability of non-toxic 
materials for development of polymer-drug conjugates, poor drug loading capacity, 
and difficulties in scale up from lab to commercial level (Park, Lee et al. 2008; Greco 
and Vincent 2009; Duncan 2011).  Liposomes emerged as suitable carrier for 
anticancer drug compounds and have advantages over polymer nanoparticles for the 
formulation of therapeutics (Fenske, Cullis et al. 2001).  The materials used in 
liposome preparations are safe and it also has the advantage of high drug loading 
capacities (Cullis, Mayer et al. 1989; Kulkarni, Betageri et al. 1995).  Moreover, the 
scale up of liposome in commercial setup is also feasible as evident from the number 
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of commercially available liposome products.  A detail discussion on the overview of 
liposomes, preparation of liposomes, materials used for its preparation, and various 






Figure 4: Types of nanocarriers for drug delivery. A, polymeric nanoparticles: polymeric 
nanoparticles in which drugs are conjugated to or encapsulated in polymers. B, polymeric 
micelles: amphiphilic block copolymers that form to nanosized core/ shell structure in 
aqueous solution. The hydrophobic core region serves as a reservoir for hydrophobic drugs, 
whereas hydrophilic shell region stabilizes the hydrophobic core and renders the polymer to 
be water-soluble. C, dendrimers: synthetic polymeric macromolecule of nanometer 
dimensions, which is composed of multiple highly branched monomers that emerge radially 
from the central core. D, liposomes: self-assembling structures composed of lipid bilayers in 
which an aqueous volume is entirely enclosed by a membranous lipid bilayer. E, viral-based 
nanoparticles: in general structure are the protein cages, which are multivalent, self-assembles 
structures. F, carbon nanotubes: carbon cylinders composed of benzene rings (adapted from 







Table 2: Various types of nanoparticulate drug delivery systems and their characteristics 
(adapted from Cho, Wang et al. 2008). 
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1.6 Liposome as drug delivery system for anticancer therapy 
 Liposomes are spherical, self-closed structures formed by one or several 
concentric lipid bilayers with an aqueous phase inside and between the lipid bilayers 
(Sessa, Weissmann 1968; Samad, Sultana et al. 2007).  Liposomes have come a long 
way as a pharmaceutical carrier since it was first introduced by Sir Alec Bangham in 
the year 1961 as a phospholipids spherule, and have offered some unique advantages 
as drug delivery system which include a) encapsulation of both hydrophilic and 
hydrophobic drugs; b) protection of encapsulated drug from degradation by reducing 
its interaction with plasma components ; c) targeting of tumour cells and other organs 
by surface coating the liposome with specific ligands ; and extension of the residence 
life time of the drug (Bangham , Standish et al. 1965; Gregoriadis, Wills et al. 1974; 
Mayer, Tai et al. 1989).   
The first generation of liposomes (conventional liposomes) consisted of 
mixture of phospholipids such as egg phosphatidylcholine or 
distearoylphosphatidylcholine and sterol such as cholesterol.  The major advantage 
offered by these conventional liposomes over free drugs is reduced exposure of 
encapsulated drug to the normal tissues and decreased clearance.   For example, 
cardiotoxicity is the major dose-limiting side effect of doxorubicin but preclinical 
studies have shown that conventional liposomal doxorubicin, given at doses 
comparable to free doxorubicin, demonstrates significantly reduced cardiotoxicity 
(Kanter, Bullard et al. 1993).  Presently, three of the four marketed liposome 
formulation belong to the first generation of liposome and includes Myocet TM 
(liposomal doxorubicin), Daunosome (liposomal daunorubicin) and Depocyt 
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(liposomal cytarbine).  One of the drawbacks of the use of these conventional 
liposomes is the fast elimination from the blood and the capture of the liposomal 
preparations by the cells of the reticulo-endothelial system (RES), primarily in the 
liver (Kupffer cells).  This has led to the emergence of second generation of liposome 
which consisted of sterically stabilized liposomes where surface grafted amphiphilic 
polymers such as poly (ethylene glycol) are incorporated into the liposome to 
prevent/reduce its uptake from RES (Senior, Delgado et al. 1991; Papahadjopoulos, 
Allen et al. 1991; Harris and Chess 2003).  Conjugation of these polymers to liposome 
has resulted in a decrease identification of liposome by opsonins and subsequent 
clearance by RES and therefore longer circulation time and increased tumor 
accumulation of drug were observed as compared to the conventional first generation 
liposomes (Klibanov, Maruyama et al. 1990).  The commercially available second 
generation liposome includes Doxil® (pegylated liposomal doxorubicin).  The 
circulation half life was found to be three times higher for Doxil® than Myocet TM, a 
first generation liposome (Gabizon, Catane et al. 1994).  The third generation of 
liposome involves the attachment of ligands on the liposomes against the cell surface 
antigens expressed selectively on tumor cells so as to increase the therapeutic efficacy 
of encapsulated drugs.  There is no commercially available third generation liposome 
formulation.  However, research attempts have been carried out on folate mediated 
liposome targeting (Lee and Low 1994), transferrin mediated liposome targeting 
(Gottesman, Pastan et al. 1996; Hatakeyama, Akita et al. 2004) and antibody mediated 
liposome targeting (Allen 2002; Lukyanov, Elbayoumi et al. 2004).   The fourth 
generation of liposomes is designed to release the drug at the tumor site in response to 
external stimuli such as heat (Sandstrom, Ickenstein et al. 2005; Woo, Chiu et al. 
2008), magnetism (Kubo, Sugita et al. 2000; Dandamudi and Campbell 2007) and 
22 
 
ultrasound (Negishi, Omata et al. 2010; Suzuki, Namai et al. 2010).  Use of 
heat/temperature to increase the release of drug from liposome at the target site has 
been studied extensively and has gained considerable interest.  ThermoDox, a 
liposomal doxorubicin formulation that releases its content at around 42ºC, is under 
clinical trials for breast and hepatocellular carcinoma (Landon, Park et al. 2011).  
Liposomes approved for clinical use are enlisted in Table 3.  Besides these approved 
liposomal products, there are many novel liposomal formulations which are currently 
undergoing clinical trials either as a single liposomal injection or in combination 
along with other drugs (Table 4).   
   Recently, liposome has gained significant attention for its ability to deliver 
drug cocktails (Mayer, Harasym et al. 2006; Mayer and Janoff 2007). Co-
encapsulation of two drugs into the liposomes allows the coordination of the release 
of two drugs in systemic circulation and thereby helps deliver the two drugs in a 
controlled manner at the desired synergistic drug molar ratio at the tumor site (Mayer, 
Harasym 2006).  Various liposomal drug cocktails that are presently under preclinical 
or clinical trial have shown promising outcomes.  A summary of these liposomal drug 
cocktails is provided in Table 5. 
Table 3: Anticancer drugs containing liposomal products approved for clinical use  
Drug Product name Indication 
Doxorubicin DoxilTM , CaelyxTM 
 
Kaposi sarcoma in AIDS 
Myocet®, Evacet® Refractory ovarian cancer,  
metastatic breast cancer 
Daunorubicin 
citrate 















Product  Indication  Clinical trial 
Phase  
Liposomal 
doxorubicin   
Liver and breast cancer Phase  I 
Liposomal irinotecan Advanced solid tumor , Colorectal cancer 
 
Phase  I,  Phase 
II 





Lung disease cancer, Ewings sarcoma Phase II 
Liposomal topotecan Small cell lung cancer, ovarian cancer, 
solid tumors 
Phase  I  
Liposomal  lurtotecan Ovarian Neoplasms Phase II 
Liposomal vincristine Soft tissue sarcoma, Lymphoma 
Leukemia, Wilms tumor, Osteosarcoma,  
Acute Lymphoblastic Leukemia,  
Malignant Melanoma 
Phase  I,  Phase 
II 
Liposomal vinorelbine Solid tumors, Hodgkins disease, Non-
Hodgkins lymphoma 
Phase  I 





Solid tumors Phase  I 
Liposomal  cisplatin Ovarian Cancer,  Pancreatic Cancer Phase II, Phase 
III 
Liposomal paclitaxel Neoplasm,  Solid tumors,  Advanced 
Gastric Carcinoma,  Esophageal Cancer 




Leukemia , Kaposi Sarcoma  Phase  I,   Phase 
III 
Liposomal annamycin Breast cancer Phase  I,  Phase 
II 
Liposomal docetaxel Solid tumors Phase  I 
Liposomal oxaliplatin B-cell lymphoma , colorectal cancer 
 
Phase  I,  Phase 
II 
Liposomal BLP25  
(peptide derived from 
mucin 1) 
Non small cell lung cancer Phase II 
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1.7 Types of liposome and methods of preparation 
Based on the size and number of lipid bilayer present, liposomes can be 
mainly classified as multilamellar vesicles (MLVs) and unilamellar vesicles (ULVs).  
MLVs are consisted of 5-25 lipid bilayers, whereas ULV are consisted of single lipid 
bilayer as the name suggested.  MLVs have diameters of around 1 micrometer and are 
heterogeneous in size.   MLVs are not widely used for delivery of antitumor drugs, 
whereby liposome of size less than 200 nm is desired so as to selectively penetrate 
tumor capillaries (Liu, Mori et al. 1992).  However, MLVs have found to be effective 
in delivery of drugs used to treat lung disorders, whereby liposome of size more than 
1 micrometer is desired so as to avoid phagocytic clearance from lung periphery and 
deliver the drugs into deeper tissues of lungs (Dhand 2004; Edwards, Ben-Jebria et al. 
1998; Verschraegen, Gilbert et al. 2004).  ULV can be further classified as small 
unilamellar vesicle (20-100 nm), medium unilamellar vesicle (around 100 nm) and 
large unilamellar vesicle (more than 100 nm) (Samad, Sultana et al. 2007).  The size 
of the liposomes prepared varies based on the method used for preparing the 
liposomes (Lasic and Papahadjopoulos 1995).  The various methods that are being 
used for preparing different kinds of liposomes include a) detergent dialysis, b) 
hydration upon removal of organic solvent, and c) extrusion method (Samad, Sultana 
et al. 2007).  Among all these methods, the extrusion method has gained widespread 
acceptance for preparation of liposomes.  It involves the extrusion of a heterogenous 
population of fairly large liposomes through polycarbonate membranes under 
moderate pressures.  This technique produces liposome of narrow size distribution 
and defined size (Mayer, Hope et al. 1986).  In addition, it requires low cost 
equipment, is rapid and feasible for scale up when compared to other methods.   
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A schematic diagram demonstrating steps involved in the preparation of MLV and 






Figure 5: A schematic diagram demonstrating steps involved in preparation of liposome 
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1.8 Lipids used for liposome preparation 
Liposomes are made of three main types of materials: 1) phospholipids and 
sphingolipids 2) Cholesterols and 3) polyethylene glycol conjugated lipids.  The 
following sections give an overview of the physicochemical properties of the three 
lipid materials. 
1.8.1 Phospholipids and sphingolipids 
Phospholipids are building blocks of liposome.  A phospholipid has a polar 
head group, a phosphate group and two hydrophobic fatty acid containing acyl chains 
connected by the glycerol backbone at C-1 and C-2 positions, with a polar moiety 
attached to the C-3 position forming the head group region (Figure 6) (Chapman 
1975). At physiological pH, the phosphate group of the phospholipids possess 
negative charge.  This negative charge of phosphate group can be neutralised by the 
presence of positively charge head groups, such as choline or ethanolamine.  Thus, at 
physiological pH, choline/ethanolamine containing phospholipids would be 
zwitterionic. On the other hand, the head group such as serine and glycerol possess 
neutral charge and therefore phosphatidylserine and phosphatidylglycerol containing 
phospholipids would have net negative charge (Vance 2002).  Presence of a small 
amount of charged lipids helps prevent aggregation, thereby improving drug retention 
and stability during shelf life of the product (Maurer-Spurej, Wong et al. 1999).  
However, presence of excessive amount of positively or negatively charged lipid on 
the surface of liposome may result in increased opsonin binding in plasma which may 
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cause destabilization of liposome and subsequent rapid release of drug and clearance 
of the liposome carrier by macrophages (Juliano and Stamp 1975).  
The hydrocarbon chain of phospholipids can vary in length and degree of 
saturation.  In general, the length of hydrocarbon acyl chains found in liposomes 
varies from 12 to18 carbons, and up to three double bonds can be found in the acyl 
chain.  The most common acyl chains used for liposome preparation include myrtistic 
(C14), palmitic (C16), and stearic (C18).  Alterations in chain length can affect 
stability, permeability, and phase behaviour of liposomes (Anderson and Omri 2004).  
Another important factor of phospholipids that affects liposome performance is phase 
transition temperature of phospholipids.  Phase transition temperature (Tc) is that 
critical point where lipids undergo a gel-to-liquid crystalline phase transition.  At a 
temperature corresponding to Tc, a maximum in liposome leakiness is observed 
(Risbo, Jorgensen et al. 1997).  Different phospholipids have different Tc and hence 
have different drug release characteristics.  Also, higher the Tc, higher is the half life 
of liposome in the systemic circulation (Gregoriadis and Senior 1980; Senior 1987).    
Sphingolipids are another kind of phospholipid and consist of fatty acid, a 
sphingosine moiety and a polar head group (Simard and Gerzanich. 2006).  The 
fundamental structural unit common to all sphingolipids is ceramide, which bears a 
simple –OH on C-1 of the sphingosine moiety (Figure 7).  The most commonly used 
sphingolipid is sphingomyelin.  Presence of sphingolipid in the liposomal formulation 
has been shown to reduce the permeability of lipid membrane through the formation 
of hydrogen bonds (Bally, Tardi et al. 2000).  Commonly used phospholipids for the 
preparation of liposome along with their transition temperature (Tc) and molecular 








Table 6: Commonly used phospholipids for the preparation of liposome along with their 
transition   temperature (Tc) and molecular weights (adapted from Samad Sultana et al. 2007) 
 
 
Phospholipids  Abbreviation Charge Tc (0C) Mol. Wt. 
Brain Sphingomyellin  BSPM  0  32  814 
Dimyristoyl phosphatidylcholine  DMPC  0  23  678 
Dipalmitoyl phosphatidylcholine  DPPC  0  41  734 
Distearoyl phosphatidylcholine  DSPC  0  58  790 
Dioleyl phosphatidylcholine  DOPC  0  -22  786 
Dilaruryl phosphatidylglycerol  DLPG  -1  4  633 
Dimyristoyl phosphatidylglycerol  DMPG  -1  23  689 
Dipalmitoyl phosphatidylglycerol  DPPG  -1  41  745 
Distearoyl phosphatidylglycerol  DSPG  -1  55  796 
Phosphatidyl ethanolamine  PE  0  48  720 
Dimyristoyl  
phosphatidyl ethanolamine  
DMPE  0  --  636 
Dipalmitoyl  
phosphatidyl ethanolamine  
DPPE  0  60  692 
Distearoyl  
phosphatidyl ethanolamine  
DSPE  0  --  748 
Dimyristoyl phosphatidic acid  DMPA  -2  51  618 
Dipalmitoyl phosphatidic acid DPPA  -2  67  649 
Dioleoyl phosphatidic acid DOPA  -2  --  701 
Dipalmitoyl phosphatidyl serine  DPPS  --  48  758 
























Figure 7: Structure of a Sphingolipids 
 
Fatty acid chains 











 Cholesterol is another common constituent of liposome. Structurally 
cholesterol is different from phospholipids and sphingolipids; however, due to its 
ampiphatic nature it can still be incorporated into the lipid bilayer membrane of 
liposome.  Cholesterol has a 4 membered sterol ring, a hydrophilic hydroxyl group 
and a short alkyl chain (Israelakvilli, Marcelja et al. 1980) (Figure 8).  Cholesterol is 
normally added into the liposome at around 20-50% of the total composition.  
Cholesterol confers stability to the liposomes in vivo, as it seems to reduce liposome 
interaction with plasma protein (Moghimi and Patel 1988; Drummond, Meyer et al. 
1999).  In addition, cholesterol enhances the retention of entrapped hydrophilic drugs 












1.8.3 Poly (ethylene glycol) conjugated lipids 
Besides the above mentioned materials, liposomes are conjugated to 
amphiphilic polymers to improve its stability in vivo and increase circulation time.  
Various polymers such as poly ethylene glycol (PEG), poly (acrylloyl) morpholine 
(PacM), poly (acrylamide) (PAA), and poly (vinylpyrrolidone) (PVP) have been 
conjugated to liposome so as to improve its circulation life time in vivo (Torchilin, 
Shtilman et al. 1994).  Among the various polymers, PEG has been found to be most 
effective and safe as compared to other polymers investigated.  PEG is a non toxic 
polymer.  It has been approved by Food and Drug Administration (FDA) for use in 
cosmetics, foods, pharmaceuticals including injectable formulations (Harris and Chess 
2003).  It is available in different molecular weights; however, the most optimal 
molecular weight that has been found to be effective in extending the circulation time 
of liposome is 2000 (de Gennes 1987; Woodle and Lasic 1992; Dos Santos, Allen et 
al. 2007).  PEG can be chemically conjugated onto the surface of pre-formed 
liposomes, or they can be derivatized to lipid molecules to form polymer-lipid 
conjugates and subsequently incorporated into liposomes (Robert, Bentley et al. 
2002).  One of the most widely used PEG-lipid is DSPE-PEG 2000 (Figure 9).  The 
density of PEG that is commonly used for stabilizing neutral liposomes in vivo is 5 to 
8 mol%.  Addition of PEG to the liposome surface has provided the modified 
liposomes extended circulation life time and reduced macrophage system recognition 
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(Senior, Delgado et al. 1991).  Doxil is an example of liposome grafted with PEG-
lipid. This formulation is reported to have higher plasma area under the concentration 
time curve (AUC) as compared to non-pegylated liposomal doxorubicin, and is 
believed to correlate with better therapeutic efficacy (Drummond, Meyer et al.1999).   
However, a comparative study between pegylated and non-pegylated 
liposomal doxorubicin study suggest that both the formulations offers similar efficacy 
and addition of PEG to liposomal doxorubicin does not provide significant 
enhancement of therapeutic index when compared to non-pegylated one (Hong, 
Chang et al. 1999).  In addition, PEG coating to liposomal doxorubicin (Doxil) results 
in preferential accumulation of Doxil in the skin, resulting in subsequent leakage of 
doxorubicin in the surrounding tissues leading to a side effect called as palmar plantar 
erythrodysesthesia (PPE), more commonly known as hand-foot syndrome (Swenson, 
Janoff et al. 2005).  Thus, the use of PEG coating is not always essential and can be 








Figure 9: Structure of 1, 2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[amino 









1.9 Drug encapsulation into liposome 
Liposome is consisted of an aqueous core and a hydrophobic lipid bilayer and 
thus is a suitable drug carrier for encapsulation of hydrophilic as well as hydrophobic 
drug molecules.  Efficient drug encapsulation into liposome is of prior importance as 
it controls the pharmacokinetic and biodistribution profile of drugs and thereby results 
in improved therapeutic index (Drummond, Meyer et al. 1999).  Stable and efficient 
liposomal encapsulation of drugs can be achieved using passive and active 
encapsulation techniques, based on the properties of drugs to be encapsulated (Allen 
and Stuart 1999).  For passive encapsulation, the drug is loaded into the liposome 
during the formation of liposome.  Passive encapsulation for hydrophilic drugs can be 
achieved by mixing drugs with the aqueous buffer, followed by hydrating the lipid 
film with this drug solution (Allen and Stuart 1999).  The amount of hydrophilic 
drugs that can be passively entrapped into liposome primarily depends on the aqueous 
trapped volumes, the ability of the drug to cross the lipid bilayer and its solubility.  
Passive encapsulation for hydrophobic drugs can be achieved by mixing the drug with 
lipids dissolved in organic solvent, followed by thin drug/lipid film formation via 
solvent evaporation. The trapping efficiency for hydrophobic drugs into liposome by 
passive encapsulation is governed mainly by the drug membrane partition-coefficient.  
Passive encapsulation typically offers low encapsulation efficiency, particularly for 
hydrophilic drugs (Mayer, Wong et al. 1988).  The low encapsulation efficiency with 
passive encapsulation technique results in large proportion of un-encapsulated drug 
left outside the liposome, which needs to be removed before liposome could be used.  
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Though separation of un-encapsulated and encapsulated drug from liposome can be 
easily achieved with the help of column chromatography or dialysis in lab setting, the 
removal of un-encapsulated drug fraction from liposomes manufactured for large 
scaled production batches is comparatively more tedious and challenging process.  
Thus, to improve encapsulation efficiency and thereby avoid the step of removal of 
un-encapsulated drug from liposome, alternative drug loading techniques are needed.  
This has prompted the development of alternative drug loading techniques into 
liposome such as active drug encapsulation.  Drug such as amphotericin, taxol, and 
annamycin, have been successfully loaded into the liposome using the passive 
encapsulation technique (Mayer, Madden et al. 1993; Chonn and Cullis 1995). 
Active drug encapsulation refers to those techniques whereby the drug is 
loaded after the liposomes have been formed (i.e. into preformed liposomes), unlike 
passive encapsulation method where the drug is added during the liposome 
preparation.  Active encapsulation techniques offer close to 100 % drug loading 
efficiency (Mayer, Bally et al 1985; Mayer, Bally et al. 1986).  Two main techniques 
can be employed to actively encapsulate drugs into liposome:    a) pH gradient, and b) 
transition metal ion gradient.   In pH gradient method, accumulation of drugs into the 
liposome is brought about by establishing transmembrane pH gradient across the 
liposome lipid bilayer.  There are three different methods that are widely used to 
generate pH gradient.  First method involves hydration of liposome with acidic buffer 
(pH ~3.5-4.0) followed by the exchange of buffer in the exterior of liposomes with a 
buffer in the range of pH 7.5 (Madden, Harrigan et al. 1990; Harrigan, Wong et al. 
1993). Thus, the difference in the pH environment in the interior and exterior of 
liposome leads to generation of pH gradient across the lipid bilayer of liposome.  This 
method utilizes the fact that certain drugs may exist in both charged and uncharged 
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forms depending on the pH of their environment.  Such drug molecules once added to 
an aqueous phase in the unprotonated state (neutral), permeates into the liposome 
aqueous core through the lipid bilayer.  Once inside the liposome core, the drug 
molecules get protonated due to the acidic pH.  These charged molecules are then 
unable to pass through the lipid bilayer and return to the external medium and 
therefore gets trapped in the interior of the liposomes.  For example, liposomes 
prepared in a low pH buffer (such as citrate buffer at pH 4) are passed down a size 
exclusion column to exchange for an external buffer (such as hepes buffered saline 
[HBS] at pH 7.5) to generate the transmembrane pH gradient and facilitate loading of 
doxorubicin (Figure10). Second method involves hydrating liposome with ammonium 
sulphate [(NH4)2SO4] followed by the exchange of buffer in the exterior of liposome 
with sodium chloride (NaCl) salt solution. This causes high concentration of 
[(NH4)2SO4] inside the liposome.  As a result of this, NH3 diffuses out from the 
interior to the exterior of liposome leaving behind one proton for every NH3 lost, 
leading to generation of pH gradient.  For example, liposome prepared in ammonium 
sulphate (NH4)2SO4 are passed down a size exclusion column to exchange for an 
external buffer (such as 145 mM NaCl) to generate the transmembrane pH gradient 
and subsequent loading of doxorubicin (Haran, Cohen et al. 1993) (Figure 10).  Third 
method for generation of pH gradient involves addition of ionophore to the liposome.  
Ionophores are group of organic compounds that form a complex with an ion and 
transport it across the membrane (Pressman 1976).  Drug loading into liposome using 
ionophore relies on this ion translocating property of ionophore.  The ionophore 
couples the outward movement of cations (such as Mn2+, Cu2+) from the interior of 
liposome to the inward movement of protons from the external buffer, thus acidifying 
the liposome interior and thereby establishing the pH gradient (Fenske, Wong et al. 
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1993) (Figure 11).    For example, liposomes are first prepared in manganese sulphate 
buffer (MnSO4) at pH 3.4 followed by exchange with external buffer (such as sucrose, 
hepes, EDTA buffer (SHE) at pH 7.5) using size exclusion column chromatography 
technique so as to generate the transmembrane manganese ion gradient. The solution 
of ionophore calcimycin (A23187) is subsequently added to this mixture.  Ionophore 
A23187 exchanges Mn2+ from the liposome core with the proton ion from the external 
SHE buffer, resulting in generation of pH gradient, leading to loading of irinotecan 
(Messerer, Ramsay et al. 2004).  Drug such as doxorubicin, vincristine, and topotecan 
have been successfully loaded into the liposome using the pH gradient technique 
(Mayer, Madden et al. 1993; Abraham, Edwards et al. 2004; Waterhouse, Madden et 
al. 2005). 
Besides pH gradient, other method employed for active encapsulation of drugs 
into liposome includes transmembrane metal ion gradient generated by usage of 
transition metal ion (Figure 11).  This technique is based on the complexation 
between the metal ion and drug molecule.  Drug molecules possessing co-ordination 
sites to form complex with transition metal are suitable candidates for this type of 
loading.  Various transition metals that have been explored for drug loading using this 
technique include Mn2+, Cu2+ and Zn2+.  Drugs such as doxorubicin, vincristine, 
mitoxantrone, irinotecan and topotecan have been efficiently loaded using 
transmembrane metal ion gradient (Abraham, McKenzie et al. 2004; Taggar, Alnajim 
2006; Ramsay Alnajim 2007; Li , Cui et al. 2008; Cui, Li et al. 2009; Tardi, Dos 































Figure 10: Drug loading via pH gradient: using citrate buffer (10a) and using ammonium 
sulphate buffer (10b): (10A) (1) Liposome hydrated with citrate buffer with pH of 4. (2) Then 
liposome exterior is exchanged with buffer such as HBS with pH 7.5, this difference in the 
interior and exterior of liposome results in generation of pH gradient (3) Neutral doxorubicin 
(DOX-NH2) diffuses into the liposome interior under the influence of pH gradient, becomes 
protonated and gets entrapped inside the liposomes. (10B) (1) Liposome hydrated with 
ammonium sulphate buffer with pH of 5 (2) Neutral ammonia diffuses out of the liposome 
vesicle leaving behind one proton (3) Neutral doxorubicin (DOX-NH2) diffuses into the 
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Figure 11: Transition metal ion and ionophore mediated drug loading technique: (1) 
Liposome hydrated with copper sulphate or ferrous sulphate or manganese sulphate with an 
internal pH of 3.5 (2) Free doxorubicin (DOX-NH2) diffuses into the acidic liposome interior 
to form a complex with copper ion or ferrous ion (3) Doxorubicin-metal ion complex forms 
within the aqueous core leading to drug retention within the liposome. (4) A23187 causes the 
influx of two hydrogen ions to the liposome interior for every divalent cation (e.g Mn2+, Cu2+ 
or Fe2+) effluxed. This ensures preservation of pH gradient across the liposome for loading of 






















THESIS RATIONALE, RESEARCH HYPOTHESIS AND OBJECTIVES 
2.1 Thesis rationale/research hypothesis 
Ovarian cancer is the sixth most common cancer of women, and accounts for 
the greatest number of deaths from gynaecological malignancies worldwide.  In 
Singapore, ovarian cancer remains the fifth most deadly among the gynaecological 
cancers and now surpasses cervical cancer in prevalence.  Majority of the patients 
suffer from relapse within a relatively short period of time despite initial response to 
paclitaxel or platinum-based chemotherapy. Alternative approaches of treatment in 
such patients are limited, and include the use of topoisomerase inhibitors such as 
topotecan, irinotecan, doxorubicin, and etoposide, either as a single agent or in 
combination. Despite their useful antitumor effects, the use of topoisomerase 
inhibitors as single agent suffers from two main disadvantages which are emergence 
of secondary malignancies and development of drug-resistant tumor cells (Felix 1998; 
Mistry, Felix et al. 2005; Azarova, Lyu et al. 2007; Saraiya, Gounder et al. 2008).  
Topoisomerase II inhibitors when used alone have been reported to induce 
chromosomal translocation leading to secondary leukemia (Felix 1998; Mistry, Felix 
et al. 2005; Azarova, Lyu et al. 2007).  Emergence of drug-resistant tumor cells have 
been reported when topoisomerase I inhibitors are used as single agent (Saraiya, 
Gounder et al. 2008). To overcome these issues, the use of combination chemotherapy 
of topoisomerase I inhibitor plus topoisomerase II has been suggested (Salerno, Da 
Settimo et al. 2010).   
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A Phase II clinical study using the combination of topoisomerase inhibitors, 
irinotecan (topoisomerase I inhibitor) and doxorubicin (topoisomerase II inhibitor), 
has shown promising outcome in the treatment of platinum-resistant ovarian cancer 
patients.  Moreover, the study demonstrated that the response rate of irinotecan and 
doxorubicin in combination is more effective than that of irinotecan monotherapy.  
However, the study also suffered from adverse side effects, more than 90 % of the 
patient volunteers suffered from two major drug related toxicities namely neutropenia 
and diarrhea.  Therefore, despite the promising outcomes of this study the clinical use 
of these drugs is restricted, mainly due to dose dependent toxicity associated with the 
free form of doxorubicin and irinotecan.  Two possible reasons could explain the 
occurrence of these drug related toxicities.  First, both the drugs are administered as 
saline based free drug injections and drugs are able to traverse the regular body 
vasculature and distribute in the normal tissues of body.  Second, the dose of each 
drug is selected near the maximum tolerated dose (MTD), which will expose the 
normal body tissues to high amount of free drugs.  The end result is the emergence of 
broad range of toxicities to the patients following this combination regimen, leading 
to decreased therapeutic index.   It is thus conceivable that MTD dosing of anti-cancer 
agents in a saline based formulations may not have fully exploited the potential 
synergistic effects that exist among the agents in a combination regimen.  In order to 
overcome this issue, alternative strategy of dose optimization called as “ratiometric” 
dosing has been suggested.  In ratiometric dosing, the therapeutic effect of drug 
combinations is often dependant on the molar ratio of the individual drugs in the 
regimen, where synergistic effect occurs when tumors are exposed to fixed synergistic 
molar drug ratios, which are identified in vitro using cell culture based techniques.  
Moreover, it is important to understand that synergism could only be achieved in vivo 
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if the various agents exist at synergistic molar drug ratios in the blood and at the site 
of action, which is nearly impossible with saline based free drug cocktails as each 
drug follows its own pharmacokinetic behavior, after intravenous administration.   
This highlights the need to develop appropriate drug delivery systems so as to 
deliver the two drugs in the synergistic drug ratio to the tumor cells.  In this case, a 
carefully designed drug carrier system that could encapsulate the drug combination in 
the synergistic ratio as well as deliver such drug ratio to the tumor site would be of 
great value in improving the therapeutic efficacy and safety.  Advances in 
nanotechnology have provided opportunity to address these issues.  Nano-scaled drug 
carriers such as nanoparticles, liposomes and polymer-drug conjugates have gained 
wide interest as pharmaceutical carrier for delivery of anticancer drugs and other 
chemotherapeutic agents.  Liposomes are arguably the most advanced nano-scaled 
delivery system available, with several liposome based products already approved for 
human use.  Some examples of the approved liposome formulations containing single 
anticancer drugs are Doxil (doxorubicin), DaunoXome (Daunorubicin citrate), 
Depocyt (cytarbine), liposomal-Annamycin (Annamycin) and VincaXome 
(vincristine).   Recently reported studies have indicated that besides delivering single 
drug, liposomes can also be used for efficiently delivering drug cocktails.  The 
examples of co-encapsulated liposomes under clinical evaluation include CPX-351 
(Cytarabine: Daunorubicin), CPX-1 (Irinotecan HCI: Floxuridine), and CPX-571 
(Irinotecan HCl: Cisplatin).  Co-encapsulated liposomes carrying drug cocktails offer 
advantages such as synchronized in vivo release of entrapped drugs in the defined 
synergistic molar drug ratio, reduced reticuloendothelial clearance, and enhanced 
permeability and retention-mediated tumor accumulation, which may reduce side 





To the best of our knowledge, no research group has co-encapsulated 
irinotecan and doxorubicin in a single liposomal formulation, nor demonstrated 
therapeutic benefit of such a co-encapsulated liposomal formulation in treating 
ovarian cancer. Thus, it is hypothesized that an optimized liposome formulation co-
encapsulating doxorubicin and irinotecan in the synergistic ratio will achieve 
significantly better treatment outcomes when used to treat animal models of ovarian 
cancer.  In addition, this drug combination will achieve improved therapeutic efficacy 
and reduced toxicity at drug doses that are much lower than the maximum tolerated 
dose (MTD) of doxorubicin and irinotecan.  The success of this project may provide a 
better alternative to the current treatments, particularly for platinum refractory type of 
ovarian cancer.  Ultimately this will help to improve the quality of life for women 
suffering from ovarian cancer worldwide. 
 
2.2 Research objectives 
The overall objective of this thesis is to develop novel co-encapsulated 
liposome containing two topoisomerase inhibitors doxorubicin and irinotecan for 
treating ovarian cancer with reduced toxicity and improved efficacy.  With the 
advancement in the field of liposome technology, sophisticated cocktail liposomes 
encapsulating two or more drugs in a synergistic ratio with coordinated release 
properties and improved stability profile can be designed. The main focus of this 
thesis is to identify synergistic ratio of doxorubicin and irinotecan and engineer the 
various components in the liposome so as to achieve functional properties essential 






1) To evaluate the effect of doxorubicin and irinotecan (as single agents and in 
combination) on ovarian cancer cell proliferation/viability and use these data to 
identify the molar ratio of the two drugs in combination required to produce 
synergistic activity at doses lower than MTD of doxorubicin and irinotecan.  
The results of this objective are described in section 4.1, where these two drugs were 
evaluated in three different ovarian cancer cell lines (SKOV3, OVCAR3, and 
IGROV-1) as single agents and in combination of three different molar drug ratios 
(1:1,1:10 and 10:1).  
 
2) To develop and optimize liposomal formulation co-encapsulating doxorubicin 
and irinotecan (in the synergistic molar ratio obtained from first objective), and 
to assess how the developed liposomal preparation influenced release and 
stability of doxorubicin and irinotecan. 
The results of this objective are described in section 4.2, where series of studies were 
conducted with an aim of investigating the best liposomal formulation that can be 
further tested in animal for its in vivo performance. Mainly the effect of the various 
hydration media (MnSO4 / CuSO4 / FeSO4 / (NH4)2SO4/ citrate) on loading efficiency, 
in vitro release and stability of drug entrapped into the liposomes were studied.  In 
addition, the imaging of liposome using cryo-TEM and computational studies for 







3) To evaluate the efficacy of the liposomal formulation co-encapsulating 
doxorubicin and irinotecan for the treatment of ovarian cancer bearing murine 
models.   
The results of this objective are described in section 4.4, where pharmacokinetic 
parameters and therapeutic efficacy for liposome co-encapsulating the two drugs were 
evaluated and compared with that of saline based free drug cocktails.  
In Chapter 5 of this thesis, the summary discussion and conclusion of this research 
project will be discussed from the formulation and clinical perspective. Additionally, 
other potential benefits that could be further explored using this formulation will be 



















MATERIALS AND METHODS 
 
3.1 Materials  
Distearoyl-sn-glycero-3-phosphocholine (DSPC) was obtained from Avanti 
Polar Lipids (Alabaster, AL, USA).  Cholesterol, A23187 ionophore, Sephadex G-50, 
and all other chemicals were obtained from Sigma-Aldrich (Singapore).  Doxorubicin 
hydrochloride and irinotecan hydrochloride trihydrate were purchased from the 
National University Hospital (NUH), Singapore.  SN38 was purchased from Sigma- 
Aldrich (Singapore) and doxorubicinol was gifted by Prof. B. Chowbay (National 
Cancer Center, Singapore).  Slide-A-Lyzer was purchased from Thermo Scientific 
(USA).  Ovarian cancer cell lines SKOV-3 and OVCAR-3 were purchased from 
American Type Culture Collection (Manassas, USA).  IGROV-1 cell line was a 
generous gift from Prof. Larry H. M. (Wayne State University, School of Medicine, 
USA).  Dimethyl sulphoxide (DMSO), 2-(3, 5-diphenyltetrazol-2-ium-2-yl)-4, 5-
dimethyl-1, 3-thiazole bromide (MTT), chloroform were purchased from MP 
Biomedicals, Inc. (Singapore). Fetal bovine serum (FBS) was purchased from 
Hyclone Laboratories (Logan, UT, USA).  Balb/c mice were purchased from Centre 
for Animal Resources, National University of Singapore (NUS) (Singapore), while 
CB17/Icr-Prkdcscid/IcrIcoCrl SCID mice were purchased from Charles River 









3.2 In vitro cytotoxicity assay studies and data analysis 
In vitro cytotoxicity assay studies were performed using 2-(3, 5-
diphenyltetrazol-2-ium-2-yl)-4,5-dimethyl-1,3-thiazole bromide (MTT) colorimetric 
assay (Mosmann 1983).  Briefly, cells (SKOV-3, OVCAR-3, and IGROV-1) were 
harvested, and cell viability was determined by trypan blue exclusion.  Only cell 
samples with viability >90% were used.  Cells were seeded at 5000 per well in a 96-
well, flat-bottomed culture plate, and were allowed to adhere overnight before 
exposure to drug treatment (including doxorubicin or irinotecan alone or in 
combination administered as free drugs at three molar ratios: 1:1, 1:10, and 10:1).  
The cells were subsequently incubated for 72 h at 37°C in the CO2 incubator, and at 
the end of incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT, MP Biomedicals Inc., France) was added to the cells at a final concentration of 
0.2 mg/mL.  After incubating for 4 h at 37°C, culture medium was removed from each 
well, and 150 µL dimethylsulfoxide (DMSO) was added to solubilize the purple 
formazan precipitate to allow measurement of absorbance at 570 nm in a microtiter 
plate reader (Tecan Infinite™ 200, Tecan Trading AG, Switzerland).  Cell viability 
was determined based on the absorbance readings and expressed as a percentage of 
the vehicle control as follows: cell viability = [(absorbancetest – absorbanceblank) / 




Data obtained from the above MTT assay were subject to median effect 
analysis using the CalcuSynR software (version 2 (Biosoft, Cambridge, UK). The 
CalcuSynR   program determines if the combined agents act in additive,synergistic or 
antagonistic manner by using the mean cell survival percentages from the MTT assay 
as a function of drug concentrations to generate a Combination Index (C.I.).  C.I could 
be computed by the following equation: C.I. = [(D) 1 / (Dx) 1] + [(D) 2 / (Dx) 2], where 
D1 and D2 represent doses of drug 1 and drug 2, respectively, used in the combination 
to induce a defined effect (e.g. 50% cell death), and (Dx) 1 and (Dx) 2 represent the 
doses of drug 1 and drug 2 , respectively, required to have the same effect when the 
two drugs are administered as single agents.  C.I. <1, ~1 and >1 represent synergistic, 
additive and antagonistic effect for a drug combination, respectively. 
 
3.3 Liposome preparation  
All liposomes were made of DSPC/Cholesterol in the molar ratio of 55:45.  
Liposomes were made by thin film hydration method (Mayer, Tai et al. 1989).  
Briefly, lipids were dissolved in chloroform, and the resultant solution was evaporated 
under a gentle stream of nitrogen gas to remove chloroform.  The lipid samples were 
subsequently placed under vacuum for a minimum of 2 h to remove any residual 
solvent.  The dried lipid films were hydrated at 60ºC using different solutions, 
including citrate/ MnSO4 / MnCl2 / CuSO4 / FeSO4 / (NH4)2SO4 with concentration of 
300 mM unless otherwise specified with pH adjusted to 3.5.  The multilamellar 
vesicles (MLV) were then extruded 10 times at 65ºC through stacked polycarbonate 
filters of pore sizes of 0.1 and 0.08 µm (Whatman, Inc., Clifton, NJ) using the 
extruder device (Northern lipids, Vancouver, BC, Canada).  The size of the resultant 
liposome sample was determined by quasi-elastic light scattering (QELS) using the 
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Malvern ZetaSizer HS3000 (Malvern Instruments, Herrenberg, Germany) and had 
diameters around 110 nm.  Phospholipids concentrations were determined using the 
well established phosphate assay (Fiske and Subbarow 1925). 
 
3.4 Loading of doxorubicin and irinotecan into preformed liposomes  
Doxorubicin and irinotecan were actively loaded into preformed liposome 
using transmembrane metal ion gradient and ionophore-mediated pH gradient 
(Abraham, Mckenzie 2004; Messerer, Ramsay et al. 2004).  Firstly, a transmembrane 
ion gradient was established through the exchange of the external buffer using 
Sephadex G-50 column pre-equilibrated with SHE buffer pH 7.5 (300 mM sucrose, 
20 mM HEPES, 15mM EDTA).  For drug loading, it was performed at 60°C at a lipid 
concentration of 5μmol/mL unless specified otherwise.  The initial drug-to-lipid molar 
ratio for loading was 0.2:1 unless specified otherwise. The molar ratios of doxorubicin 
and irinotecan co-encapsulated into liposomes were 1:1 unless specified otherwise.  
To maintain the pH gradient across the liposomes, the ionophore A23187 was added 
to some of the liposome preparations at a concentration of 0.2 µg/µmol lipid and 
incubated for 10 min before the addition of the drug.   A23187 is an electro-neutral 
ionophore that exchanges internal divalent metal ion with external H+ in a 1:2 ratio to 
establish a transmembrane pH gradient (Fenske, Wong et al. 1998).  At indicated time 
point, 100 µL of the liposome-drug mixture was sampled and separated on a 1-mL 
Sephadex G-50 spin column equilibrated with SHE buffer (680g for 3 min) to 
remove any unencapsulated drug.  To determine the amount of drug accumulated into 
liposomes, the eluted liposome fraction was divided into two aliquots for the 
determination of drug and lipid contents.  To measure drug concentrations, 100 µL of 
the eluted liposomes from spin column was mixed with 900 µL of 1% Triton X-100, 
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and placed in a water bath of > 90°C for 1-2 min.  Subsequently, the sample was 
cooled to room temperature before measuring the absorbance at 480 nm for 
doxorubicin and 370 nm for irinotecan using a UV spectrophotometer (UV-1601, 
Shimadzu) (Abraham, Mckenzie 2004; Messerer, Ramsay et al. 2004).  Lipid 
concentrations were determined by the phosphate assay (Fiske and Subbarow 1925).  
The drug encapsulation efficiency was expressed either as drug-to-lipid molar ratio or 
as percentage of drug-to-lipid molar ratio.  The drug encapsulation efficiency was 
estimated using the below equation (Zhao, Wu et al. 2008). 
Encapsulation efficiency (%) = [measured liposomal encapsulated drug/total drug)] x 100 
 
3.5 In vitro drug release study  
In vitro drug release assay from liposomal formulations were performed by 
incubation with fetal bovine serum (FBS) (Fenske, Wong et al. 1998).  Briefly, 
Liposome samples were mixed with (FBS) such that the final lipid concentration was 
1 μmol/mL and the final serum concentration was 50%.  The samples were incubated 
at 37°C, and at the indicated time points (1, 4, 24, 48 and 72 hours), 100 µL aliquots 
were taken and placed onto 1-mL Sephadex G-50 spin columns.  Percent drug release 
was calculated from the below equation (Zhao, Wu et al. 2008). 
Drug release (%) = ([Drug concentration at t0– Drug concentration at t] ÷ Drug 
concentration at t0) ×100 
 











3.6 Stability study  
The stability of the liposome formulations co-encapsulating doxorubicin and 
irinotecan as a combination was monitored with storage temperatures ranging 2–8ºC 
for a period of 8 or 24 weeks.  At indicated time points, the liposome samples were 
analyzed for size, polydispersity and drug content.  Percentage of drug released over 
the study period was calculated using the below equation. 
Drug release (%) = ([Drug concentration at t0– Drug concentration at t] ÷ Drug 
concentration at t0) ×100 
 
Where t0 represents week 0 and t represents storage after a given week  
 
3.7 Computational study: Quantum mechanical methods 
DMol3 module in material Studio software was used for studying drug-metal 
interaction. Geometry optimization was carried out using LDA-VWN functional and 
double numerical plus polarization basis set. Energies were refined by calculating 
single point energies using GGA-PW91 functional and DNP basis set. Optimization 
was carried out using +2 charges and spins unrestricted.  
 
3.8 Atomic absorption spectroscopy (AAS) study 
A PerkinElmer AAnalyst 400 model flame atomic absorption spectrometer 
equipped with deuterium lamp background correction, a hallow cathode lamp (HCL) 
and an air acetylene burner was used for the determination of the manganese. The 
instrumental parameters were as follows: wavelength, 279.48 nm for manganese; 
bandpass, 1.0 nm; lamp current, 9.0 mA; fuel flow rate, 1.0 L/min (Sanzolone and 
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Chao 1977). Doubly distilled deionized water and analytical reagent grade chemicals 
were used unless otherwise specified.  Manganese stock solutions (each 1000 µg/mL) 
were prepared by dissolving the appropriate amounts of manganese (II) sulphate. The 
working solutions were prepared by dilution from the stock solution. Co-encapsulated 
liposome preparation containing irinotecan and doxorubicin prepared using 
manganese sulphate (with or without ionophore) at different concentrations (150, 300, 
600, and 750 mM) were passed through the Sephadex G 50 spin column and the 
eluted sample was then further diluted before subjecting to atomic absorption 
spectrophotometer. 
 
3.9 Cryo-Transmission Electron Microscopy (TEM)  
Cryo-TEM analysis was carried out by the research staff under supervision of 
Dr. Edwards (Uppsala University, Sweden). Briefly, cryogenic transmission electron 
microscopy (cryo-TEM) was performed on empty and drug-loaded liposomes using a 
Zeiss EM 902A transmission electron microscope (LEO Electron Microscopy, 
Oberkochen, Germany) operated at 80 kV in the zero-loss bright-field mode.  Digital 
images were recorded under low-dose conditions with a BioVision Pro-SM Slow Scan 
CCD camera (Proscan GmbH, Scheuring, Germany) and analySIS software (Soft 
Imaging System, GmbH, Münster, Germany).  To visualize maximum detail, an under 
focus of 1–2 μm was used to enhance the image contrast.  Sample preparation was 
performed at 25°C and ~99% relative humidity within a climate chamber.  A small 
drop (~2 μL) of sample was deposited on a copper grid covered with a perforated 
polymer film coated with carbon on both sides.  Excess liquid was removed by 
blotting with filter paper, leaving a thin film of the solution on the grid. Immediately 
after blotting, the sample was vitrified by plunging the grid into liquid ethane held at –
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182°C.  Samples were maintained below −165°C and protected against atmospheric 
conditions during both transfer to the TEM and examination. 
 
3.10 UPLC analytical method development and analysis  
A Waters AcQuity Ultra High performance Liquid Chromatography (UPLC) 
system (USA) was used to quantify doxorubicin and irinotecan obtained from mice 
plasma during pharmacokinetic studies. A Waters AcQuity UPLC, BEH C18, 1.7 µm, 
2.1 x 150 mm column protected by guard column was used. Using gradient trials the 
assay was performed at 25ºC (sample temperature) and 40ºC (column temperature) 
with water with 0.1 % v/v formic acid as aqueous phase and acetonitrile with 0.1% 
v/v formic acid as organic phase. The following gradient was employed: 85% aqueous 
(0-1min) followed by 70% aqueous (1-4 min) and finally back to 85 % aqueous (4-
7min).  The run time was 7 minutes at flow rate of 0.5 ml/min.  Detection 
wavelengths for both the drugs were kept at 254 nm. 
The extraction procedure for doxorubicin and irinotecan from plasma sample 
were modified from previously reported method (Poujol, Pinguet et al. 2003; Gilbert, 
McGeary et al. 2005; Bansal, Awasthi et al. 2008).  Protein precipitation technique 
was employed.   Briefly, 50 µl of mice plasma was spiked with known amounts of 
doxorubicin, irinotecan, SN-38, doxorubicinol along with 10 µl of internal standard 
camptothecin (CPT) and vortex mix for 20 seconds.  To this, 150 µl of a mixture of 
ice cold acidified methanol: acetonitrile (1:1) (acidification of methanol was carried 
out using 0.1 % v/v formic acid) was added and vortex mix for 20 seconds (to 
denature the proteins) followed by centrifugation at 10,000 rpm for 10 minutes.  After 
centrifugation, the supernatant was then evaporated using nitrogen flush.  This 
residual was then reconstituted with mobile phase and 5µl was then injected onto the 
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UPLC column for analysis. The concentration of doxorubicinol, doxorubicin, SN-38 
and irinotecan in the sample was determined by comparing the peak ratios of the 
sample versus a calibration curve obtained by spiking known amounts of analytes into 
pooled mice plasma.  Empower 2 software (Waters) was used to control the system 
and for all the integrations and data processing. Pharmacokinetic analyses were 
performed using noncompartmental analysis with WinNonlin software standard 
Version 1.0 (Scientific Consulting Inc., USA). 
3.11 Animal studies 
 All the mice used were six to eight weeks-old female mice and weighed 
between 20-22 g. They were housed in micro-isolator cages in a pathogen free animal 
bio-safety level-2 (ABSL-2) facility and given free access to food and water. They 
were quarantined for 7 days before the study was initiated. All procedures involving 
the use and care of mice were performed humanely in conformity with the National 
Advisory Committee for Laboratory Animal Research (NACLAR) guidelines. All 
studies were conducted according to the protocols approved by the National 
University of Singapore Institutional Animal Care and Use Committee (IACUC: 
protocol number 06/07(A7)11).   
3.11.1 Pharmacokinetics studies 
Both free drug cocktail and co-encapsulated liposomes (1:1 molar ratio of 
doxorubicin and irinotecan corresponding to 10 micromole/kg of doxorubicin and 10 
micromole/kg of irinotecan) were injected intravenously into the lateral tail vein of 
female Balb/c mice.  At 5, 15, 30, 60, 120, 240 minutes for free drug cocktail group 
and 0.5, 1, 2, 4, 8 and 24 hours for co-encapsulated liposomes group, the animals were 
euthanized with carbon dioxide asphyxiation and the blood collected by cardiac 
puncture (3 mice per time point).  Blood samples were centrifuged for 10 minutes at 
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1000 g to isolate the plasma and stored -80ºC until assay (Poujol, Pinguet et al. 2003; 
Gilbert, McGeary et al. 2005). 
3.11.2 In vivo efficacy study 
The in vivo efficacy study was conducted according to the protocol approved 
by IACUC.  Eighteen female CB 17 SCID mice were inoculated intra-peritoneally 
with 5 x 106 IGROV1 cells (day 1).  After 14 days of tumor inoculation, mice were 
randomly divided into 3 groups (6 per group) and were injected intravenously with 1) 
0.9% saline (control), 2) Free drug cocktail containing doxorubicin and irinotecan and 
3) co-encapsulated liposomal preparation containing doxorubicin and irinotecan.  The 
dose of doxorubicin was given at 10 micromole/kg (2/3rd of MTD) and irinotecan 
was administered at 10 micromole/kg (1/10th of MTD).  A total of 3 doses on day 14, 
day 17 and day 23 of the study were administered.  At these values, the molar ratio of 
doxorubicin: irinotecan was 1:1.  Body weight of the mice was monitored thrice 
weekly until day 60.  Besides body weight, dried spleen weight of the mice was also 
monitored as it serves as an indication of disease progression.  Spleen was collected 
immediately after mice were sacrificed. All mice were monitored daily for a decrease 
in physical activity, signs of pain and other signs of disease progression.  Severely ill 
animals or animals showing weight loss or gain in excess of 20% were euthanized by 
an overdose of carbon dioxide (CO2).  Animal survival was recorded daily from the 
day of tumor cell inoculation (day 1) to determine the effectiveness of various 
treatment groups.  Endpoint was stipulated at 60 days after cancer cell inoculation 
according to the regulations of the IACUC.  Mice surviving till the end of the 
experiment were termed as long term survivors (LTS) and euthanized on day 60. 
Percentage weight change at nadir was calculated from the following equations: 
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Weight change at nadir (%) = [weight before treatment-weight at nadir/ weight before 
treatment] x 100 
 
 
3.12 Statistical analysis 
Data were expressed as standard errors mean (± SEM).  Effects of the drug 
loading mechanisms on the encapsulation efficiency of doxorubicin and irinotecan 
were analyzed using one-way analysis of variance (ANOVA) and the Student’s 
independent sample t-test.  One-way ANOVA was used to assess changes in drug 
retention over time; means of individual time points were compared post-hoc using 
Tukey’s Honestly Significantly Different test while repeated measures ANOVA was 
carried out to compare drug release patterns among the various hydration media 
overtime (PASW programme, version 18, for windows).  Kaplan-Meir survival curves 




















RESULTS AND DISCUSSION 
4.1 In vitro evaluation of anti-proliferative activities: identification of synergistic 
ratio of doxorubicin: irinotecan using ovarian cancer cell lines 
4.1.1 Section overview 
Drug combination chemotherapy is the mainstay of cancer treatment (Devita, 
Serpick et al. 1970; Schwartz and Smith 1976; Keppen 2010).  However, the success 
of combination therapy lies in 1) the selection of appropriate combination of drugs, as 
not all drug combinations are effective with treatment outcome being antagonistic 
(Frei 1991; Greco, Bravo et al. 1995) and 2) the delivery of the drug combination in 
the fixed synergistic ratio to the tumor cells (Mayer, Harasym et al. 2006; Mayer and 
Janoff 2007).  In this section, irinotecan and doxorubicin will be first evaluated as 
single agent, for their antiproliferative activity against IGROV-1, SKOV-3, and 
OVCAR-3. Subsequently they will be combined in several different molar ratios to 
determine the best synergistic ratio required to produce maximum cancer cell killing 
effect in ovarian cancer cell lines.  Irinotecan is a topoisomerase-I inhibitor similar to 
topotecan, a drug approved by the Food and Drug Administration (FDA) for the 
second-line treatment of ovarian cancer (Wang 1985; Kunimoto, Nitta et al. 1987).  
Doxorubicin is a topoisomerase-II inhibitor, an FDA approved drug for treatment of 
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ovarian cancer (Gabriella, Giacomo et al. 2010).  Both of these drugs are 
recommended in those patients who are suffering from metastatic ovarian cancer, and 
initial or subsequent chemotherapy with paclitaxel and cisplatin has failed (Gordon, 
Fleagle et al. 2001; Bodurka, Levenback et al. 2003).  Recent clinical trial data have 
suggested that the combination of doxorubicin and irinotecan may be synergistic 
when administered together to treat ovarian cancer (Nishimura, Tsuda et al. 2007).  
Based on these reports doxorubicin and irinotecan were identified to be constituted as 
combination regimen in the current project.     
4.1.2 Section results 
The three ovarian cancer cell lines used for evaluation included IGROV-1, 
SKOV-3, and OVCAR-3 as these are the standard cell lines used in evaluating the 
performance of anticancer compounds used for the treatment of ovarian cancer.  First, 
the each cell line was treated separately with various concentrations of irinotecan and 
doxorubicin 72 hours.  Cell viability was determined by the MTT assay.  Figure 12 
shows the viability of IGROV-1, SKOV-3, and OVCAR-3 against different 
concentrations of irinotecan and doxorubicin as single agents.  CalcuSyn® software 
was used to estimate effective concentration needed to kill 50 % of total cell 
population (EC50).  The EC50 values indicate the potency of the drug, while the r 
values show goodness of fit for the data to the median-effect equation used to 
calculate EC50, which were given in Table 7.  In order to compare the potency of 
irinotecan and doxorubicin in the three different cell lines, the EC50values for 
irinotecan and doxorubicin were estimated and summarized in Table 7.  Among the 
three cell lines, OVCAR-3 was the most sensitive cell line, and displayed EC50 values 
for irinotecan of 7.91 µM as well as for doxorubicin of 0.179 µM.  In addition, 
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doxorubicin was found to be more potent than irinotecan in all the three cell lines 
tested, with EC50 values ranging from 0.1 to 0.7 µM (Table 7).  The next step is to 
evaluate the antitumor activity of irinotecan and doxorubicin as combination regimen 
against the three cell lines and assess whether the effect produced by the combination 
is more (synergistic), equal (additive) or less (antagonistic) than that produced by 
irinotecan or doxorubicin as monotherapy. 
          
            
       
 
Figure 12: Effect of irinotecan and doxorubicin as single agents on the viability of IGROV-1, 
OVCAR-3 and SKOV-3 ovarian cancer cells.  Cells were treated with the indicated 
concentrations of drugs for 72 h.  Cellular viability was assessed using MTT assay. Results 

































































































































Table 7:  EC50 (µM) of irinotecan and doxorubicin IGROV-1, OVCAR-3 and SKOV-3 
ovarian cancer cells. The values were estimated using the Calcusyn software version 2.0. Cell 
viability data obtained from the MTT assay of irinotecan and doxorubicin on the three ovarian 
cancer cell lines were pooled from at least 3 independent sets and were used for the 
computation.  Values in the parentheses represent the upper and lower 95 % confidence 
intervals of the EC50 estimations.  
 
Drug IGROV-1 OVCAR-3 SKOV-3 
 EC50 (µM) 
 
r EC50 (µM) r EC50 (µM) r 





























For drug combination studies, fixed molar ratio combinations of irinotecan and 
doxorubicin were evaluated over a range of concentrations. Specifically, the two 
drugs were administered at molar ratios of 1:1, 1:10 and 10:1.  The MTT assay was 
used to determine cell viability after 72 hours of drug exposure.  Figures 13, 14, and 
15 show the viability of IGROV-1, OVCAR-3, and SKOV-3 respectively against 
different concentrations of irinotecan and doxorubicin as drug combinations. 
However, based on these sigmoidal dose-response curves, it is difficult to determine if 
the drug treatment effect is synergistic or not.  Therefore, the measure of synergy 
between the two drugs was analyzed from the median-effect analysis method of Chou 
and Talalay (Chou and Talalay 1984) and the combination index (C.I.) value was 
derived using the CalcuSyn software.  The plot of C.I. against fraction affected (fa) 
for the various fixed ratio combinations of irinotecan/doxorubicin in IGROV-1, 
OVCAR-3 and SKOV-3 ovarian cancer cell lines are presented in Figure 16.  The 
data displayed in Figure 16 provides overall information about the ability of the 
various irinotecan-doxorubicin combinations to produce cancer cell killing effect at 
different levels (fa).  However, what is of more importance is to evaluate if the drug 
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combination is synergistic at maximum cancer cell kill; therefore, the C.I. values were 
estimated at an effect level of 90% cell kill (ED90)  for the various ratios and are 
summarized in Table 8.  As can be seen in Table 8, C.I. values at ED 90 indicated that 
all the three molar ratios (1:1, 1:10 and 10:1) evaluated were synergistic in SKOV3 
and IGROV-1.  However, in OVCAR-3, only 1:1 molar ratio was found to be 
synergistic, whereas 1:10 and 10:1 were found to be antagonistic as the C.I was found 
to be more than 1.1 (Table 8).   In summary, the irinotecan: doxorubicin molar ratio of 
1:1 appears to be the most promising, with synergistic interaction between irinotecan 
and doxorubicin observed at higher cell killing effect level (ED90) in all three ovarian 
cancer cell lines tested.  Furthermore, irinotecan: doxorubicin as a drug combination 
at 1:1 molar ratio allowed substantial dose reduction at higher cell killing effect level 
(ED90) when compared to the single agents (Figure 17).  Therefore, the development 
of a liposome formulation that co-encapsulates irinotecan and doxorubicin would be 















Figure 13: Effect of irinotecan and doxorubicin as combination on the viability of IGROV-1 
ovarian cancer cells.  Cells were treated with the indicated concentrations of drugs for 72 h.  
Cellular viability was assessed using MTT assay. Results shown are means ± SEM from three 









































































Figure 14: Effect of irinotecan and doxorubicin as combination on the viability of OVCAR-3 
ovarian cancer cells.  Cells were treated with the indicated concentrations of drugs for 72 h.  
Cellular viability was assessed using MTT assay. Results shown are means ± SEM from three 







































































Figure 15: Effect of irinotecan and doxorubicin as combination on the viability of SKOV-3 
ovarian cancer cells.  Cells were treated with the indicated concentrations of drugs for 72 h.  
Cellular viability was assessed using MTT assay. Results shown are means ± SEM from three 







































































Figure 16: In vitro screening of irinotecan and doxorubicin for synergism in (A) OVCAR-3 
and (B) SKOV-3 (C) IGROV-1 ovarian cancer cells.  The irinotecan/doxorubicin molar ratios 
used were 1:1 (), 1:10 () and 10:1 ().  Data points represent the C.I. values estimated 
from data pooled from three independent sets of MTT assays, each with triplicate 
determinations.  C.I. values of <1, ~1 and >1 indicate synergism, additivity and antagonism, 
respectively.   
 
  




Combination Index (CI) at ED90 
SKOV-3 r OVCAR-3 r IGROV-1 r 
1:1  0.5682 0.9943 0.4294 0.9422 0.6386 0.9348 
1:10 0.4429 0.9622 1.1357 0.9308 0.6892 0.9699 
10:1 0.4088 0.9698 1.7955 0.8259 0.5794 0.9433 
 
Results from the MTT viability assay were pooled from the three independent studies and 
used to compute CI values using Calcusyn software version 2.0.  The reported values were 
based on the drug concentration to achieve 90 % cell kill.  CI < 1, ~1, or > 1 denotes a 













































Figure 17: The drug concentration required to achieve 90 % cell kill of irinotecan alone (clear 
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4.1.3 Section discussion 
Combination chemotherapy has been in use since it was first tested in 1960’s 
by Frei and coworkers.  From a clinical perspective, drug combinations offer the 
advantage of reducing the risk of developing acquired resistance from the use of 
single drug for long period of time.  Moreover, if a particular antitumor drug 
combination is synergistic, it would offer additional benefit of reducing the dose and 
subsequent dose related toxicities, yet without compromising efficacy.  Recently, it 
has been reported that the anticancer activity of chemotherapeutic agents, when used 
in combination, depends on the fixed ratio of the two drugs used in the combination 
regimen (Mayer, Harasym et al. 2006; Harasym, Tardi et al. 2007; Mayer and Janoff 
2007).  Thus, while analyzing in vitro drug-drug interactions in cell culture, 
approaches that typically combine two drugs at fixed ratio and subsequently use the 
data of this study for determining synergy would be useful.  Median effect analysis for 
evaluating synergy developed by Chou et al. (as discussed in Chapter 1) is based on 
combining two drugs in fixed ratio (Chou and Talalay 1984).  This method of 
evaluating in vitro synergy by Chou et al. has been found to be a good predictor of in 
vivo synergy (Abraham, McKenzie et al. 2004; Mayer and Janoff 2007; Tardi, 
Johnstone et al. 2009).  By using median-effect analysis, drug ratio dependant 
synergism is reported for irinotecan in combination with gemcitabine, cisplatin and 
floxuridine (Bahadori, Ogretmen et al. 1998; Messerer, Ramsay et al. 2004; Tardi, 
Dos Santos et al. 2009).   Similarly, drug ratio dependant synergism for doxorubicin is 
reported with dasatinib, panobinostat, interleukin 1 alpha, and dexrazoxane (Sinha, 
Monti et al. 1993; Mimnaugh, Monti et al. 1992; Maiso, Colado et al. 2009; Pichot, 
Hartig et al. 2009). In the present study, a systematic approach of combining 
irinotecan and doxorubicin in fixed ratio was adopted and subsequently, the 
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synergistic or antagonistic effects of these two drugs on three ovarian cancer cell lines 
were determined using median effect principle.  To the best of our knowledge, no in 
vitro cell viability assay has been conducted till date to evaluate the synergistic effect 
of these two drugs as combination in ovarian cancer cell lines. Ours is the first attempt 
in this direction. 
In the present study, we studied the effects of these two drugs on three 
different ovarian cancer cell lines: OVCAR-3, IGROV-1, and SKOV-3, both as single 
agent and in combination.  First, the effect of these two drugs were tested as single 
agents in ovarian cancer cell lines to determine their EC50 values, and the two drugs 
were then combined in arbitrary ratios during the combination studies to determine 
the most synergistic ratio using Chou and Talalay method.   This method of synergy 
determination is widely used as it has biological relevance, and the in vitro results 
have been shown to be an appropriate predictor on whether the combination regimen 
would work in vivo in a synergistic, additive or antagonistic manner (Abraham, 
Mckenzie et al. 2004; Tardi, Dos Santos et al. 2009).  For drug combination studies, 
evidence of synergism was observed in all the three ovarian cancer cell lines, when 
doxorubicin and irinotecan were combined at molar ratio of 1:1.  Most importantly, 
the concentration of irinotecan could be reduced by several folds when combined with 
doxorubicin in 1:1 molar ratio, while maintaining the biological/cytotoxic activity 
(Figure 17). This would aid in potentially minimizing dose related toxicity such as 
myelosuppresion and diarrhea, which are associated with the long term use of 
irinotecan (Rothenberg 2001).  The possible mechanism of action responsible for the 
synergism of these two drugs may be the upregulation of topoisomerase-II in tumor 
cells induced by the presence of topoisomerase-I inhibitor (irinotecan) (Denny 1997; 
Stahl, Sabine et al. 1997; Eder, Chan et al. 1998; Vey, Kantarjian et al. 1999).  There 
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might be other additional factors responsible for the synergistic activity of these 
drugs.  So far, there is no report explaining the precise mechanism for synergistic 
activity of these drugs and further in depth investigation is warranted to understand it 
in a better way (Voigt, Matsui et al. 1998; Barrows, Holden et al. 1998). 
 Based on the results presented in this section, appropriately designed liposome 
systems will be generated to co-encapsulate the two drugs in the fixed molar ratio of 















4.2 Formulation development and characterization of liposome co-encapsulating 
irinotecan and doxorubicin  
4.2.1 Section overview 
Delivery of multiple agents in a single liposome formulation has emerged as 
an attractive area in liposomal delivery (Mayer, Janoff et al. 2007).  However, the co-
encapsulation of two drugs into liposomes is not without challenge. Loading 
procedures which allow efficient and stable encapsulation of each drug into the 
liposomes are necessary.  The important factors that affect encapsulation and retention 
of drugs in the liposomes include lipid composition, stability of the ion gradient, 
buffer capacity (for pH gradient loading) and loading temperature (Mayer, Tai et al. 
1989; Mayer, Wong et al. 1988; Drummond, Meyer et al. 1999; Johnston, Edwards et 
al. 2008).  In this section, the co-encapsulation of doxorubicin and irinotecan in 
liposomes will be attempted.  The co-encapsulation of two drugs into the liposome is 
considered as efficient when a) the drugs are loaded into the liposome with 
encapsulation efficiency of at least 80 %, b) the desired synergistic ratio of the two 
drugs is maintained during drug encapsulation, storage and release. The two drugs 
will be encapsulated in the synergistic ratio of 1:1 based on the in vitro cell-based 
screening data presented in section 4.1. Transmembrane metal ion gradient and 
ionophore mediated pH gradient will be utilized for the co-encapsulation of 
doxorubicin and irinotecan into DSPC/cholesterol based liposome. The current 
section is further divided into several sub-sections to cover the development and 
characterization of the co-encapsulated liposome formulation.  The subsections 
include selection of suitable hydration medium for liposome preparation, in vitro drug 
release and storage stability studies of the liposome formulations co-encapsulating 
doxorubicin and irinotecan.   
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4.2.2 Section results 
4.2.2.1 Selection of suitable hydration media for efficient and stable co-
encapsulation of doxorubicin and irinotecan. 
Doxil, a commercial product of liposomal doxorubicin, is prepared through the 
use of ammonium sulphate ((NH4)2SO4) as the hydration medium for liposomes which 
generates the transmembrane pH gradient for drug loading  (Allen and Martin 2004).  
A detailed description of liposomal drug loading mechanism using ((NH4)2SO4) as 
hydration medium is covered in Chapter 1 and could be referred to understand better.  
Our first attempt at co-encapsulating doxorubicin and irinotecan was based on this 
method.  As can be seen in Figure 18, while doxorubicin loaded efficiently into the 
co-encapsulated formulation with drug-to-lipid molar ratio of 0.19 (loading efficiency 
of 95 %), however the loading efficiency of irinotecan was below optimum with drug-
to-lipid molar ratio of 0.15 (loading efficiency of 75 %).  The other most commonly 
used technique for generating transmembrane pH gradient involves hydration of 
liposome with citrate buffer and exchanging the buffer in the exterior of liposomes 
with a buffer in the range of pH 7.5 (Madden, Harrigan et al. 1990; Harrigan, Wong et 
al. 1993).  Thus, an attempt was made at co-encapsulating doxorubicin and irinotecan 
using this method.  As can be seen in Figure 18, while doxorubicin loaded efficiently 
into the co-encapsulated formulation with drug-to-lipid molar ratio of 0.2 (loading 
efficiency of 100 %), the loading efficiency of irinotecan was less optimal, with drug-
to-lipid  molar ratio of 0.13 (loading efficiency of 65 %).  The inefficient co-
encapsulation of irinotecan and doxorubicin using ammonium sulphate and citrate 
loading method prompted us to search for other loading techniques that would allow 
optimal co-encapsulation of both doxorubicin and irinotecan, with loading efficiencies 
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of at least 80% for both drugs and also would allow sufficient retention of both drugs 







Figure 18: Co-encapsulation encapsulation of doxorubicin followed by irinotecan into 
liposomes.  The liposomes were loaded with doxorubicin () followed by irinotecan () at 
drug-to-lipid molar ratio of 0.2:1 for both drugs, (A) with 300 mM (NH4)2SO4 (pH 4) as the 
internal buffer and (B) with 300 mM citrate (pH 4) as the internal buffer.  The arrow in figure 
indicates the time when irinotecan was added for loading into liposomes.  Data points 




















































Recent advances in liposome technology have resulted in emergence of newer 
drug loading techniques that provide efficient and stable retention of drug into 
liposome.  These techniques include the usage of transmembrane metal ion gradient in 
combination with ionophore (A23187) mediated pH gradient for encapsulation of 
drug entities into the liposome (Messerer, Ramsay et al. 2004; Abraham, McKenzie et 
al. 2004). A detailed description of liposomal drug loading mechanism using 
transmembrane metal ion gradient in combination with ionophore (A23187) mediated 
pH gradient as hydration medium is covered in Chapter 1.  Thus, our next attempt of 
co-encapsulation of irinotecan and doxorubicin into the liposome involved 
transmembrane metal ion gradient along with ionophore (A23187) mediated pH 
gradient. 
Liposomal co-encapsulation of doxorubicin and vincristine has been 
successfully achieved using this unique loading method with encapsulation efficiency 
of 98% for both the drugs (Abraham, McKenzie et al. 2004).  Various types of 
transition metal ions have been explored in the past so as to generate transmembrane 
metal ion gradient across the lipid bilayer of liposome (Abraham, McKenzie et al. 
2004; Taggar, Alnajim et al. 2006; Ramsay, Alnajim et al. 2008).  Selection of 
appropriate transition metal ion is of utmost importantly, as different transition metal 
ions have been shown to offer different drug encapsulating capabilities (Taggar, 
Alnajim et al. 2006).  Therefore, in order to identify the best transition metal ion salt 
that could offer efficient and stable co-encapsulation of doxorubicin and irinotecan, 
we investigated the effect of three different transition metal ion containing hydration 
medium (300 mM CuSO4, FeSO4 and MnSO4).  The two drugs were added 
sequentially to the preformed liposome beginning with doxorubicin, followed by 
ionophore A23187 and then irinotecan.  Encapsulation of doxorubicin relied on a 
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transition metal ion gradient (Cu2+, Fe2+, and Mn2+), whereas encapsulation of 
irinotecan was based on the pH gradient (generated by the addition of A23187).  Co-
encapsulation of doxorubicin and irinotecan using copper ions with A23187 produced 
adequate drug loading with drug-to-lipid molar ratios of 0.2 and 0.17, respectively 
(Figure 19), with loading efficiencies corresponding to 100 % and 85 % respectively.  
Similarly, the use of ferrous ions with A23187 produced optimum drug-to-lipid molar 
ratio of 0.19 for both drugs (Figure 19), with loading efficiency corresponding to 95 
%.  Lastly, using Mn2+ with A23187 resulted in drug-to-lipid molar ratio of 0.2:1 for 
both drugs (Figure 19), with loading efficiencies close to 100%.  
In some of the studies it is reported that the presence of ionophore A23187 
mediated pH gradient is not always necessary for encapsulation of drug entities into 
the liposome and presence of metal ion gradient alone is sufficient for efficient 
encapsulation of drug entities into the liposome (Taggar, Alnajim et al. 2006; Ramsay, 
Alnajim et al. 2007).  Therefore, we further investigated the co-encapsulation of 
doxorubicin and irinotecan using only gradient generated by transition metal ions 
(Cu2+, Fe 2+, and Mn2+), without ionophore (A23187) mediated pH gradient.  As can 
be seen in Figure 20, with the use of Mn2+ ion gradient alone, doxorubicin could be 
loaded with final drug-to-lipid molar ratio of 0.15 (loading efficiency 75%); 
irinotecan could not be loaded effectively into the liposomes, with a final drug-to-lipid 
molar ratio of merely 0.04:1 (loading efficiency 20%), which is significantly lower 
than what could be achieved with Mn2+ ion gradient + ionophore A23187 systems (p< 
0.05).  Similarly, for Fe2+ ion gradient alone, whilst doxorubicin loading reached a 
drug-to-lipid molar ratio of 0.19, loading efficiency of irinotecan was markedly 
reduced with final drug-to-lipid molar ratio of 0.11 (loading efficiency 55 %), which 
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is significantly lower than what could be achieved with Fe2+ ion gradient + ionophore 
A23187 systems (p< 0.05) (Figure 20).  
Lastly, with the use of Cu2+ ion gradient alone, drug-to-lipid molar ratios of 
0.2 and 0.17 were achieved for doxorubicin and irinotecan respectively (Figure 20) 
with loading efficiencies corresponding to 100 % and 85 % respectively.  The data 
suggested that the trend with Cu2+ ion gradient alone is similar for co-encapsulating 
the two drugs into the liposome, irrespective of presence or absence of A23187. These 
results suggested that co-encapsulation of doxorubicin and irinotecan using Cu2+ 
gradient is not dependant on the A23187 ionophore-generated pH gradient.  In 
summary, it could be inferred that Fe2+ and Mn2+ gradient alone are insufficient in 
driving both drugs into the liposome. An A23187 ionophore mediated pH gradient is 
necessary to facilitate adequate drug loading, when ferrous or manganese sulphate 
salts are used as hydration media.  On the other hand, when copper sulphate is used 
for the co-encapsulation of the two drugs in the liposomes, an A23187 ionophore 














Figure 19:  Co-encapsulation of doxorubicin followed by irinotecan into liposomes with 300 
mM (A) CuSO4, (B) MnSO4 and (C) FeSO4 as the internal buffer, in presence of ionophore, 
A23187.  The liposomes were loaded with doxorubicin () followed by irinotecan () at 
initial drug-to-lipid molar ratio of 0.2:1 for both drugs. The arrow in figure indicates the time 
when irinotecan was added for loading into liposomes.  Data points represent mean values ± 











































































Figure 20:  Co-encapsulation of doxorubicin followed by irinotecan into liposomes with 300 
mM (A) CuSO4, (B) MnSO4 and (C) FeSO4 as the internal buffer, in absence of ionophore, 
A23187.  The liposomes were loaded with doxorubicin () followed by irinotecan () at 
initial drug-to-lipid molar ratio of 0.2:1 for both drugs. The arrow in figure indicates the time 
when irinotecan was added for loading into liposomes.  Data points represent mean values ± 











































































Based on the evidence provided in Figures 19 and 20, it could be concluded 
that both doxorubicin and irinotecan can be efficiently co-encapsulated into the 
liposomes using 300 mM copper sulphate, irrespective of the presence or absence of 
ionophore A23187 mediated pH gradient. This implies that doxorubicin and 
irinotecan co-encapsulation into the copper sulphate based liposomes could be mainly 
dependent on their complexation with the copper ion rather than A23187 mediated pH 
gradient.  Thus, if this implication is true, then the amount of drug loaded should be 
proportional to the amount of copper ions available for complexation.  In order to 
confirm this possibility, we evaluated the effect of varying concentration of 
intraliposomal copper sulphate (150 mM to 600 mM) on the co-encapsulation of 
doxorubicin and irinotecan at various drug-to-lipid molar ratios (in absence of 
ionophore A23187).  As can be seen in Figure 21, indeed drug co-encapsulation in the 
copper sulpahte liposomes is mainly dependent on the concentration of copper ions 
available for complexation, particularly for irinotecan. Moreover, there is a linear 
relationship between the intraliposomal copper concentration and the total amount of 















Figure 21: Effect of varying intraliposomal CuSO4 concentration on (A) doxorubicin 
encapsulation efficiencies at various drug-to-lipid molar ratios, (B) irinotecan encapsulation 
efficiencies at various drug-to-lipid molar ratios and (C) total drug content encapsulated in the 
liposomes with efficiency of >90%.  Sequential loading was achieved with doxorubicin first 
followed by irinotecan in the absence of A23187.  In (A) and (B), irinotecan and doxorubicin 
were encapsulated at 1:1 molar ratio with the drug-to-lipid molar ratio for loading shown in 
the each figure.  In (C), the total drug content is reflected by the total drug-to-lipid molar ratio 
calculated from the summation of doxorubicin-to-lipid molar ratio and irinotecan-to-lipid 























Drug to lipid molar 
ratio 























Drug to lipid molar 
ratio 























Drug to lipid molar 
ratio 























Drug to lipid molar 
ratio 























Drug to lipid molar 
ratio 























Drug to lipid molar 
ratio 































The data displayed in Figure 21 suggested that efficient co-encapsulation of 
doxorubicin and irinotecan into the copper sulphate containing liposome in the 
absence of ionophore could actually be the result of favorable copper-doxorubicin and 
copper-irinotecan interaction rather than the transmembrane pH gradient generated via 
ionophore.  In order to confirm this possible mechanism, we evaluated the interaction 
of copper with doxorubicin and irinotecan using computational modeling (Quantum 
mechanical methods), and compared this with that of manganese, which has shown 
poor loading in the absence of ionophore.  Total energy (K cal/mol) generated from 
the metal-drug interaction was used as a means to identify which metal ion has better 
interaction with the two drugs.  Interestingly, the study demonstrated that under 
similar conditions, copper has better and stable interaction with both doxorubicin as 
well as irinotecan, when compared to the interaction of doxorubicin and irinotecan 
















Figure 22: Computational model of interaction between copper and manganese metal with 






4.2.2.2 In vitro drug release study of the liposome formulations co-encapsulating 
doxorubicin and irinotecan 
For a liposome formulation co-encapsulating two anti-cancer drugs combined 
in a molar ratio for synergistic cell killing activity, it is important to determine if the 
particular drug:drug molar ratio could be maintained when the two drugs are released 
from the liposome system in vivo.  As such, our primary aim was to examine if the 1:1 
irinotecan/doxorubicin molar ratio could be maintained when incubated with 50% v/v 
fetal bovine serum (FBS) in vitro. This study was conducted only on those liposomes 
that demonstrated efficient loading of both drugs (based on data discussed in section 
4.2.2.1).  These include liposomes that were hydrated with copper sulphate (in the 
presence or absence of ionophore A23187), ferrous sulphate (in the presence of 
ionophore A23187) and manganese sulphate (in the presence of ionophore A23187).  
Release rates for co-encapsulated liposomes hydrated with copper sulphate (with 
A23187) were most rapid in the first 4 hours of the study for both drugs, before 
gradually decreasing to final percentage retention of 61% and 46% for doxorubicin 
and irinotecan respectively (Figure 23).  Individually-loaded liposomes also exhibited 
similar release patterns in the first 4 hours of the release study, and thereafter 
percentage of doxorubicin and irinotecan remaining after 72 hours were 61% and 57% 
respectively (Figure 23).  The ratio of doxorubicin: irinotecan in the formulation 
remained at around 1.3 throughout the 72 hours (Figure 24).  Release rates for co-
encapsulated liposomes hydrated with copper sulphate (without A23187) showed a 
similar trend, where final percentage retention of 58% and 44% were achieved for 
doxorubicin and irinotecan respectively (Figure 23).  The ratio of doxorubicin: 
irinotecan in the formulation remained at around 1.28 throughout the 72 hours (Figure 
24).  Individually-loaded liposomes also exhibited similar release patterns in the first 
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4 hours of the release study and thereafter; percentage of doxorubicin and irinotecan 
remaining after 72 hours were 68 % and 66 % respectively (Figure 23).  Release 
profiles for co-encapsulated formulations hydrated with ferrous sulphate (with added 
A23187) showed a different trend from those hydrated with copper sulphate; release 
of irinotecan was more drastic compared to doxorubicin in the first 4 hours and the 
percentage of doxorubicin and irinotecan retained after 72 hours showed a significant 
discrepancy of 40% and 16% respectively (p < 0.05) (Figure 23).  The ratio of 
doxorubicin: irinotecan deviated markedly from the optimum ratio of 1:1 in the co-
encapsulated formulation, with ratios ranging from 2 to 3 over the 72-hours (Figure 
24) p < 0.05.   In contrast, the percentage of doxorubicin and irinotecan left in 
individually-loaded liposomes were 52% and 69% respectively (Figure 23).  This 
suggests that the release of one drug is affected by presence of other when both the 
drugs are co-encapsulated.  Release profiles for co-encapsulated formulations 
hydrated with manganese sulphate (with A23187) showed highest retention with 
around 65% of both the drugs being retained over the 72-h time course (Figure 23).  
Furthermore, the presence of one drug did not interfere with the release of the other 
from the co-encapsulated formulation, when the release profiles of doxorubicin and 
irinotecan from the co-encapsulated formulation were compared to those obtained 
from the respective, single-agent formulation prepared in a similar manner (Figure 
23).  The ratio of doxorubicin: irinotecan in the co-encapsulated formulations 
remained at around 1.0 throughout the 72 hours (Figure 24).  Taken together, the 
liposomes hydrated with copper sulphate (with and without ionophore) and 
manganese sulphate displayed sustained release over 72 hours, and most importantly, 
the molar ratio of the two drugs was well maintained during the course of study and 










Figure 23: In vitro release studies of the 1:1 irinotecan/doxorubicin co-encapsulated liposome 
formulation, liposomal irinotecan alone and liposomal doxorubicin alone.  The co-
encapsulated formulation was prepared by the sequential loading method with the use of 300 
mM (A) FeSO4 + A23187 (B) MnSO4 + A23187 (C) CuSO4 + A23187 (D) CuSO4 - A23187 
and at a drug-to-lipid molar ratio of 0.2:1.  The single agent formulation was prepared 
similarly without the addition of the other drug.  Data points represent mean values ± S.E.M. 
from three independent batches.  Symbols: irinotecan in co-encapsulated liposomes (); 
irinotecan alone in liposomes (); doxorubicin in co-encapsulated liposomes (); 
doxorubicin alone in liposomes (). Significant difference between co-encapsulated and 














































































       
 
 
       
 
 
Figure 24: In vitro ratio maintainence of 1:1 irinotecan/doxorubicin molar ratio co-
encapsulated in liposome formulation.  The co-encapsulated formulation was prepared by the 
sequential loading method with the use of 300 mM (A) FeSO4 + A23187, (B) MnSO4 + 
A23187, (C) CuSO4 + A23187 and (D) CuSO4 - A23187. Drug loading was carried out at 
drug-to-lipid molar ratio of 0.2:1.  Data points represent mean values ± S.E.M. from three 
independent batches. The ratio of the two drugs deviated markedly from desired 1:1 ratio in 






































































































4.2.2.3 Physical stability of the liposome formulations co-encapsulating 
doxorubicin and irinotecan 
 
Physical stability of liposomes plays a very vital role in the success of 
liposomal formulations.  The physical stability of liposomes upon storage can be 
studied by monitoring the amount of drug leaked from liposomes and by the size of 
liposomes.  In the present study, stability of the liposomes co-encapsulating 
doxorubicin and irinotecan in 1:1 molar ratio was monitored over a period of 8 weeks 
under the storage condition of 4°C.  Parameters including mean liposome diameter, 
polydispersity and drug content were used for evaluation.  This study was conducted 
only on co-encapsulated liposomes that demonstrated efficient loading and 
appropriate in vitro release profile of both drugs.  These included liposomes that were 
hydrated with copper sulphate (both in the presence and absence of A23187) and 
manganese sulphate (in the presence of A23187).   Changes in doxorubicin retention 
(over 8 weeks) did not differ significantly in liposomes hydrated with copper sulphate 
regardless of the presence or absence of an ionophore, with around 70 % of 
doxorubicin retained after 8 weeks (Figure 25) (p>0.05).  Although irinotecan 
retention in the liposome with CuSO4 + A23187 appear to decrease at a greater rate as 
compared to that in the CuSO4 - A23187 liposome, the overall difference was not 
statistically significant (p>0.05) and the percentage of irinotecan remaining at week 8 
was around 65% (Figure 25).  The doxorubicin: irinotecan ratios for preparations with 
and without A23187 were similar over the 8 weeks, with ratios ranging between 0.97-
1.17.  The size and polydispersity of CuSO4 + A23187 based liposome did not got 
affected over the 8weeks storage period; size: (week 0: 105 ± 2 nm; week 8: 107 ± 2 
nm) and polydispersity: (week 0: 0.073 ± 0.019; week 8: 0.075 ± 0.015).  Similarly, 
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the size and polydispersity of CuSO4 - A23187 based liposome did not got affected 
over the 8weeks storage period; size: (week 0: 109 ± 4 nm; week 8: 107 ± 2nm) and 
polydispersity: (week 0: 0.068 ± 0.021; week 8: 0.034 ± 0.011).  In MnSO4 + A23187 
based liposomes, over 95% of the encapsulated content was retained in the liposomes 
(Figure 25). The doxorubicin: irinotecan ratios for MnSO4 + A23187 based liposome 
was maintained as 1:1 over the 8weeks storage period.  The size and polydispersity of 
MnSO4 + A23187 based liposomes remained stable (Figure 26).   
The amount of both drugs retained after 8 weeks in MnSO4 + A23187 based 
liposomes were found to be significantly higher when compared with CuSO4 +/- 
A23187 based liposomes (p< 0.05).  Since both drugs seem to be well retained in 
MnSO4 + A23187 based liposomes, the stability study for this particular formulation 
was further extended to a total period of 24 weeks.  It was found that over 90% of the 
encapsulated content was retained in the liposomes, with the doxorubicin: irinotecan 
molar ratio of 1:1 still maintained even after evaluation of 24 weeks (Figure 26).  In 
addition, no significant changes in liposome size nor polydispersity was observed 
during the course of stability study (p> 0.05) (Figure 26).  The outcome of these 
studies is summarized in Table 9.  As can be seen in Table 9,  MnSO4 + A23187 
based liposome preparations was found to be the one with efficient loading, controlled 
release and desired stability characteristics when compared to all other formulations 





















Figure 25:  Stability studies of the 1:1 irinotecan/doxorubicin co-encapsulated liposome 
formulation.  The formulation was prepared by the sequential loading method with the use of 
300 mM (A) CuSO4+ A23187, (B) CuSO4- A23187 and (C) MnSO4 + A23187.  Drug loading 
was carried out at drug-to-lipid molar ratio of 0.2:1, and the samples were stored at 2–8°C 
over a period of 8 weeks.  At the indicated time points, the liposome formulation was 
evaluated for retention of irinotecan () and doxorubicin () in the liposomes.  Data points 
represent mean values ± S.E.M. from three independent batches. The drug retained by MnSO4 
+ A23187 based liposome after 8 weeks of storage was found to be significantly higher than 































































Figure 26:  Stability studies of the 1:1 irinotecan/doxorubicin MnSO4 + A23187 co-
encapsulated liposome formulation.  The formulation was prepared by the sequential loading 
method and was stored at 2–8°C over a period of 24 weeks.  At the indicated time points, the 
liposome formulation was evaluated for (A) retention of irinotecan () and doxorubicin () 
in the liposomes along with (B) size analysis and polydispersity of liposome samples.  Data 
points represent mean values ± S.E.M. from three independent batches.  No significant 
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4.2.2.4 Further characterization and evaluation of MnSO4+A23187 based 
liposomes co-encapsulated with doxorubicin and irinotecan.  
 
1. Simultaneous and reverse loading sequence for co-encapsulation of irinotecan and 
doxorubicin into liposome using MnSO4 + A23817 liposome 
In addition to the sequential loading procedure described in previous section 
(i.e. addition of doxorubicin followed by ionophore and then finally irinotecan), we 
have explored simultaneous  loading of irinotecan and doxorubicin, whereby the 
A23187 ionophore was added followed by concurrent addition of doxorubicin and 
irinotecan. We have also explored the reverse sequence of loading irinotecan, 
followed by the addition of ionophore for the loading of doxorubicin.  As reported 
earlier, the time required for loading of both doxorubicin and irinotecan into MnSO4 + 
A23817 liposome up to the desired drug-to-lipid molar ratio using sequential loading 
technique was around 90-180 minutes (Figure 19).  The rational for evaluating 
simultaneous loading technique was to test whether the total time required for loading 
both of the drugs could be further reduced as compared to that of sequential loading, 
yet maintaining the encapsulation efficiency or stability of liposome.  For 
simultaneous loading, the MnSO4 based liposomes were pre-incubated with the 
A23817 for 10 min before the simultaneous addition of irinotecan and doxorubicin.   
As shown in Figure 27, both drugs could be loaded with efficiencies of > 90% after 
30 min of incubation.  However, a gradual decrease in the final drug-to-lipid molar 
ratio for irinotecan and doxorubicin could be observed over the course of incubation, 
with loading efficiencies dropping to around 80% at 180 min.  This suggested that 
simultaneous mode of loading both drugs affects the retention of the two drugs inside 
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the liposome during the course of loading and thereby imparted instability to the co-
encapsulated liposome.  
The objective for reversing the order of drug addition was to investigate 
whether this would affect drug loading and retention.  In this case, irinotecan was first 
loaded into liposomes followed by the addition of the ionophore for the loading of 
doxorubicin.  As can be seen in Figure 27, irinotecan could not be loaded for first 60 
minutes in the absence of ionophore. This reconfirmed the data discussed in section 
4.2.1, where an attempt was made to load irinotecan in presence of Mn2+ gradient 
alone. However, after addition of ionophore, both irinotecan as well as doxorubicin 
could be loaded up to 100 % after 120 min of incubation. While doxorubicin was well 
retained over the 180 min duration of incubation, a gradual decrease in the final drug-
to-lipid molar ratio of irinotecan was observed, with loading efficiency dropping to 
around 85 % (Figure 27).  Taken together, sequential loading with doxorubicin 
followed by ionophore and irinotecan using MnSO4 liposomes appears to yield the 













Figure 27:  Co-encapsulation of irinotecan () and doxorubicin () into liposomes either by 
(A) simultaneous incubation of the two drugs with liposomes or by (B) reverse encapsulation 
of irinotecan followed by doxorubicin into liposomes.  Under these two conditions, drug 
loading was achieved with 300 mM MnSO4 as the internal buffer and in the presence of 
A23187.  The arrow in (B) indicates the time when doxorubicin was added for loading into 

















































2. Role of anion (chloride Vs sulphate) as the intraliposomal core on drug loading 
and retention of irinotecan and doxorubicin into MnSO4/ MnCl2 + A23817 liposomes 
As the anion may affect how the encapsulated drug precipitates in the 
liposome core (Abraham, Edwards et al. 2002), it is important to investigate the role 
of the anion inside the liposomes, which might potentially affect the extent of co-
encapsulation.  In this case, 300 mM MnCl2 was used as the intraliposomal core to 
replace MnSO4, and the loading conditions were similar to those used when 300 mM 
MnSO4 was used for the sequential loading of doxorubicin followed by irinotecan in 
the presence of A23187.  The results are presented in Figure 28.  As can be seen, both 
drugs could be loaded into the liposomes, and the drug-to-lipid molar ratios remained 
relatively constant over the incubation period of 180 min.  The final drug-to-lipid 
molar ratios for irinotecan and doxorubicin that could be achieved based on 
MnCl2+A23187 loading were 0.16 and 0.15, respectively, which corresponded to 
loading efficiencies of 80% for irinotecan and 75% for doxorubicin.  Compared to the 
loading procedure based on MnSO4+A23187, these values are significantly lower 
(p<0.05) and in agreement with those previously reported for doxorubicin loaded in a 
similar fashion (Abraham, Edwards et al. 2002). 
 
Figure 28:  Use of 300 mM MnCl2 as the internal buffer of liposomes for the sequential encapsulation 
of doxorubicin () followed by irinotecan () in the presence of A23187.  The arrow indicates the time 
when irinotecan was added for loading into liposomes.  Data points represent mean values ± S.E.M. 























3. Role of intraliposomal Mn2+ concentration on co-encapsulation of irinotecan: 
doxorubicin into MnSO4+A23187 liposomes   
In the attempt of co-delivering two drugs in liposomes, it would be desirable if 
a high loaded content for each drug could be achieved.  As such, various drug-to-lipid 
molar ratios, namely 0.1:1, 0.2:1 and 0.3:1, were loaded into liposomes by the 
MnSO4+A23187 sequential loading procedure, and irinotecan and doxorubicin would 
be loaded at the same drug-to-lipid molar ratio such that the synergistic drug/drug 
ratio of 1:1 could be maintained.  Efficient loading of irinotecan and doxorubicin 
could be achieved when a drug-to-lipid molar ratio of 0.1:1 for each drug was used 
(Figure 29).  However, when a drug-to-lipid molar ratio of 0.3:1 was used for loading, 
the final drug-to-lipid molar ratios for irinotecan and doxorubicin were 0.21:1 and 
0.24:1, respectively, which corresponded to loading efficiencies of 70% and 80% 
(Figure 29).  This reduction in loading efficiency prompted us to investigate into the 
effect of varying MnSO4 concentration inside the liposome core on loading of drugs.  
In particular, it was anticipated that increasing the intraliposomal MnSO4 
concentration could increase the amount of drug that could be loaded, as more Mn2+ 
would be available for a) the complexation with doxorubicin and b) the generation of 
the pH gradient via shuttling of protons by ionophore A23187.  Four different 
concentrations of MnSO4 were used for encapsulating the two drugs, and three 
different drug-to-lipid molar ratios were attempted at each MnSO4 concentration.  As 
shown in Figure 30, a trend could be observed in which the encapsulation efficiency 
decreased as the drug-to-lipid molar ratio increased.  Furthermore, Figure 30 
demonstrates that the total drug-to-lipid molar ratio that could be encapsulated in 
liposomes with > 90% efficiency is directly proportional to the intraliposomal MnSO4 
concentration (R2 = 0.977).  These results suggest that the drug load could reach a 
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maximum for a specific concentration of MnSO4, and a final drug-to-lipid molar ratio 





Figure 29:  Sequential loading of doxorubicin followed by irinotecan into liposomes with 300 
mM MnSO4 and in the presence of A23187 using different drug-to-lipid molar ratios.  The 
liposomes were loaded with doxorubicin (circles) followed by irinotecan (squares) at drug-to-
lipid molar ratios of 0.1:1 (solid symbols) and 0.3:1 (open symbols) for both drugs.  The ratio 
of irinotecan to doxorubicin was maintained at 1:1 molar ratio.  The arrow indicates the time 
when irinotecan was added for loading into liposomes.  Data points represent mean values ± 




































Figure 30:  Effect of varying intraliposomal MnSO4 concentration on (A) doxorubicin 
encapsulation efficiencies at various drug-to-lipid molar ratio, (B) Irinotecan encapsulation 
efficiencies at various drug-to-lipid molar ratio and (C) total drug content encapsulated in the 
liposomes with efficiency of >90%.  Sequential loading was achieved with doxorubicin first 
followed by irinotecan in the presence of A23187.  In (A) and (B) irinotecan and doxorubicin 
were encapsulated at equimolar ratio with the drug-to-lipid molar ratio for loading shown in 
the legend of each panel.  In (C), the total drug content is reflected by the total drug-to-lipid 
molar ratio calculated from the summation of doxorubicin-to-lipid molar ratio and irinotecan-
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4. Determination of residual manganese ion into MnSO4+A23187 liposomes using 
atomic absorption studies 
Since MnSO4+A23187 liposome was considered as lead liposomal 
formulation and potential formulation for in vivo animal experiments, it was essential 
to determine the residual amount of manganese left in the final liposomal preparation 
post loading, as high levels of manganese may lead to neurotoxicity if used 
chronically (Mergler and Baldwin 1997).  The amount of manganese ions left in the 
liposomal preparations loaded at different drug-to-lipid molar ratio (D/L) is shown in 
Table 10. These values when transformed in dose format (µmol Mn2+/kg; considering 
22 g as mice weight and 150µl as injection volume) were found to be well below the 
reported mice acute LD50 value of 272 µmol Mn2+/kg (Niesman, Bacic et al. 1990). 
Table 10: Residual level of manganese (ppm) present in liposomal formulation with drug 
loaded at different drug to lipid molar ratio. Data points represent mean values ± S.E.M. from 







MnSO4+A23187 liposome samples at 
different d/l molar ratio 
Residual Mn2+ (ppm) 
150 mM (loading at  D/L 0.1:1) 0.291  ± 0.005 
300 mM (loading  at  D/L 0.2:1) 0.550  ± 0.008 
600 mM (loading  at  D/L 0.4:1) 0.890  ± 0.010 
750 mM (loading  at  D/L 0.5:1) 1.534  ± 0.014 
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5. Co-encapsulation of irinotecan and doxorubicin into MnSO4 + A23817 liposomes at 
higher lipid concentration (10 µmol/mL) 
In commercial set up, it is preferable to have drug loading performed at higher 
lipid concentrations. This ultimately helps in increasing the payload of the drugs to be 
encapsulated and thereby preparing concentrated liposome preparation.  This allows 
for reducing the volume of injection to be administered at a particular dose and also 
increases the lipid dose which is sometimes desired.  Hence, we have attempted to 
increase the lipid concentration from 5 µmol/mL to 10 µmol/mL and evaluate its 
impact on drug encapsulation efficiency.  At lipid concentration of 10 µmol/mL, 
around 90 % of both drugs were encapsulated successfully in the liposome (Figure 
31).  Thus, the results demonstrated that loading for both of the drugs can be 
effectively carried out at higher lipid concentrations. 
 
Figure 31: Effect of increase in lipid concentration for the sequential encapsulation of 
doxorubicin () followed by irinotecan () in the presence of A23187 was attempted.  The 
arrow indicates the time when irinotecan was added for loading into liposomes.  Data points 
























6. Co-encapsulation of irinotecan: doxorubicin at 1:10 and 10:1 drug/drug molar 
ratios into MnSO4+A23187 liposomes 
While the drug: drug fixed molar ratio of 1:1 appears to be the most promising 
in the three ovarian cancer cell lines, it is interesting to explore, from a formulation 
development perspective, the loading of different drug: drug molar ratios into 
liposomes to see if one drug would interfere the loading of another when a large drug: 
drug ratio is to be encapsulated.  As such, two molar ratios of irinotecan/doxorubicin, 
namely 10:1 and 1:10, were attempted to be encapsulated into the liposomes using the 
MnSO4+A23187 sequential loading procedure.  As shown in Figure 32, both drugs 
could be loaded into the liposomes, with loading efficiencies of >80%. 
 
                
Figure 32:  Sequential loading of doxorubicin followed by irinotecan with different molar 
ratios of the two drugs into liposomes with 300 mM MnSO4 and in the presence of A23187.  
(A): molar ratio of irinotecan () to doxorubicin () was 10:1.  (B): molar ratio of irinotecan 
() to doxorubicin () was 1:10.  The arrows indicate the time when irinotecan was added for 









































































































7. Cryo-TEM analyses of the co-encapsulated liposome formulation prepared using 
MnSO4, with and without ionophore 
Drug precipitation within the liposomal core is well established for the 
anthracyclines (Abraham, Waterhouse et al. 2005) and camptothecins (Taggar, 
Alnajim et al. 2006).  However, no characterization has been done on the drug 
precipitation of a combination of these two types of anti-cancer drugs in the liposomal 
core.  It is thus of interest to characterize the morphology of the intraliposomal drug 
precipitate of the irinotecan/doxorubicin co-encapsulated formulation.  Several 
important observations could be drawn from Figure 33.  In contrast to the well 
characterized fiber bundle structure or “coffee bean” morphology that has been 
reported for liposomal doxorubicin (Abraham, Waterhouse et al. 2005), the 
intraliposomal drug precipitate of the co-encapsulated formulation prepared with 
A23817 exhibited a dense core without a defined structure (Figure 33).  Interestingly, 
the co-encapsulated formulation prepared without A23187 (Figure 33), which does 
not exhibit a stable transmembrane pH gradient, contained a similar intraliposomal 
drug precipitate which was without a defined structure and was smaller in amount 
compared to that prepared with A23817.  The smaller drug precipitate formed in the 
co-encapsulated formulation prepared without A23187 is likely to be attributed to a 
lower total drug content.  These results suggest that the transmembrane pH gradient 
which is critical for stable drug encapsulation of the co-encapsulated formulation may 












Figure 33: Cryo-transmission electron microscopy of various formulations including (A) 
liposomes without encapsulated drug, (B) liposomes co-encapsulated with irinotecan and 
doxorubicin in the presence of A23187, (C) liposomes co-encapsulated with irinotecan and 
doxorubicin in the absence of A23187, (D) liposomes encapsulated with irinotecan alone with 
A23187, and (E) liposomes encapsulated with doxorubicin alone with A23187.  For the co-
encapsulated formulations (B and C), the drug-to-lipid molar ratio for loading was 0.2:1 for 
each drug.  For the single agent formulations (D and E), the drug-to-lipid molar ratio for 
loading was 0.2:1.  The arrows indicate the type of drug precipitate observed in various 
formulations.  The scale bar in panel E represents 200 nm, and all micrographs are shown at 





8.  In vitro release and stability studies for 600 mM MnSO4+A23187 liposomes 
As discussed earlier, the increase in Mn2+ concentration (with A23187) 
resulted in drastic increase in encapsulation efficiency of both the drugs at high drug-
to-lipid molar ratio, with maximum of 0.9/1 total drug-to-lipid molar ratio stably 
retained in the liposome (Figure 30). This high pay load of both the drugs in single 
liposome holds great promise from formulation perspective as it allows using lower 
injection volumes during the in vivo efficacy and pharmacokinetic studies using mice 
model.  Thus, we decided to use 600 mM MnSO4+A23187 liposomes (co-
encapsulating doxorubicin and irinotecan at high total drug-to-lipid molar ratio of 
0.8/1) for in vivo efficacy and pharmacokinetic studies. We already demonstrated the 
in vitro release characteristics and stability profile of MnSO4+A23187 liposomes 
containing 300 mM MnSO4 (section 4.2.2.3).  However, since we decided to use 
MnSO4 +A23187 liposomes containing 600 mM MnSO4 for animal studies, it became 
imperative to evaluate the release and stability properties of this formulation, as a 
change in drug-to-lipid molar ratio has been reported to affect the release properties of 
liposomal products (Johnston, Edwards et al. 2008).  As can be seen from Figure 34, 
MnSO4 +A23187 liposomes prepared using 600 mM MnSO4 provided controlled, and 
most importantly, synchronized release of the two drugs.  Moreover, the stability 
profile also demonstrated that the formulation was stable throughout the study period 














Figure 34: (A) In vitro release studies profile and (B) ratio maintainence data of the 1:1 
irinotecan/doxorubicin co-encapsulated liposome formulation. The co-encapsulated 
formulation was prepared by the sequential loading method with the use of 600 mM MnSO4 + 
A23187 at a drug-to-lipid molar ratio of 0.4:1 of each drug. Data points represent mean values 
± S.E.M. from three independent batches.  Symbols: irinotecan in co-encapsulated liposomes 




















































Figure 35:  Stability studies of the 1:1 irinotecan/doxorubicin co-encapsulated liposome 
formulation; (A) drug content and (B) size/ polydispersity data. The formulation was prepared 
by the sequential loading method with the use of 600 mM MnSO4 + A23187 at a drug-to-lipid 
molar ratio of 0.4:1, and was stored at 2–8°C over a period of 24 weeks.  At the indicated time 
points, the liposome formulation was evaluated for retention of irinotecan () and 
doxorubicin () in the liposomes, size and polydispersity.  Data points represent mean values 
± S.E.M. from three independent batches. No significant difference was observed in terms of 




































































4.2.3 Section discussion 
Results gathered from the study in section 4.2.2 will be discussed in three 
aspects.  Firstly, the potential of various drug loading techniques for co-encapsulating 
doxorubicin and irinotecan will be considered.  Secondly, we will address the 
influence of loading methods on the release and physical stability profile of different 
co-encapsulated formulations.  Finally, we will discuss the outcome of the further 
characterizations carried out for the lead liposomal formulation based on 
MnSO4+A23187 sequential loading procedure. 
 When transmembrane ammonium sulphate gradient was used to co-
encapsulate doxorubicin and irinotecan, only doxorubicin was loaded to a desirable 
drug-to-lipid molar ratio (Figure 18) and irinotecan could not be sufficiently loaded to 
maintain the synergistic doxorubicin: irinotecan ratio of 1:1.  Similarly, inefficient 
encapsulation efficiency was observed with citrate buffer (Figure 18). Despite the 
evidence of success with the use of pH gradient via ammonium sulphate and citrate 
buffer in the loading of single agents (Haran, Cohen et al. 1993; Bolotina, Cohen et al. 
1994), the effectiveness of this approach in the co-encapsulation of more than one 
drug resulted in unsatisfactory drug loading efficiency. This prompted us to 
investigate a technique, alternate to ammonium sulpahte and citrate based drug 
loading so as to efficiently co-encapsulate the two drugs into the same liposome.  For 
this, we explored the use of transition metal ions gradient for co-encapsulation of 
doxorubicin and irinotecan.  Co-encapsulation was carried out using transition metal 
ion gradient alone and also in combination with ionophore (A23187) generated pH 
gradient.  Co-encapsulation was carried out sequentially; addition of doxorubicin was 
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followed by ionophore (A23187) and finally by irinotecan.  The results of drug 
loading using Cu2+, Fe2+ and Mn2+ gradients demonstrated that doxorubicin alone 
could be loaded to a considerable extent without A23187, as observed from the first 
60 minutes of drug loading data (Figure 19).  Thereafter, addition of ionophore 
A23187 resulted in shuttling of free/unbound metal ions from inside the liposomal 
core to the outside in exchange for protons present in external buffer solution and this 
process permitted generation of a transmembrane pH gradient that facilitates uptake of 
irinotecan into the liposome (Abraham, McKenzie et al. 2004).  For better 
understanding of this loading technique, schematic diagram in Chapter 1(1.9) and 
corresponding explanation could be referred.  Additionally, our results depicted that 
Cu2+ gradient could co-encapsulate doxorubicin and irinotecan to an adequate extent 
in the presence or absence of A23187 associated pH gradient (Figure 19 and 20).  The 
near optimal loading of irinotecan without an ionophore in the presence of a Cu2+ 
gradient was noteworthy (total encapsulation efficiency of > 90% was achieved, as 
shown in Figure 20).  Interestingly, although loading of irinotecan alone into liposome 
using a Cu2+ gradient in the absence of A23187 had been proven successful (Ramsay, 
Alnajim et al. 2008); our data showed that even co-encapsulation of doxorubicin and 
irinotecan was also possible with the use of Cu2+ gradient in the absence of A23187.  
This ultimately implied that optimal co-encapsulation of doxorubicin and irinotecan 
was attainable through the sole approach of a Cu2+ gradient, an observation that was 
by far, unique to this study.  The use of Fe2+ gradient, however, required an A23187-
mediated pH gradient in order for irinotecan to be loaded sufficiently (Figure 19 and 
20).  Similar to Fe2+ gradient, liposome prepared using Mn2+ gradient also required 
the presence of ionophore for efficient co-encapsulating of both drugs (Figure 19 and 
20).  The data generated for the three metal ions suggested that copper was the only 
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transition metal ion that did not require the presence of ionophore A23187 for 
maximum encapsulation efficiency.  This implied that it could be the presence of 
copper ions that acted as the driving force that load both the drugs to its maximum. 
This possibility was further confirmed by studying the impact of increasing 
concentration of Cu2+ ions on the amount of drug that can be encapsulated into the 
liposome (in the absence of ionophore).  A linear relationship was observed between 
the increase in Cu2+ ion concentration and the amount of drug loaded into the 
liposome (Figure 21), indicating that indeed copper-drug complexation could be the 
main driving force for co-encapsulating the two drugs into the liposome.  Studies 
conducted using computational modeling, where copper showed better and stable 
interaction with doxorubicin and irinotecan as compared to manganese, further 
supported our hypothesis of copper-drug complexation as a potential drug loading 
mechanism responsible for efficient co-encapsulation of two drugs into the CuSO4 
based liposome in the absence of A23187 (Figure 22).   
Taken together, metal-ion gradient and its associated ionophore-mediated pH 
gradient emerged as a viable approach in the co-encapsulation of doxorubicin and 
irinotecan when compared to ammonium sulphate gradient.  Despite adequate loading 
of doxorubicin with transmembrane pH gradient (using ammonium sulpahte and 
citrate buffer), subsequent loading of irinotecan, however, proved to be more 
successful only through the use of transmembrane metal-ion gradient in the presence 
of A23187 (Fe2+/Mn2+/ Cu2+) or in the absence of A23187 (Cu2+).  The drug release 
profiles of the co-encapsulated formulations are not significantly different from the 
drug release rates observed in individually-loaded liposomes hydrated with copper 
sulphate (Figure 23) and manganese sulphate respectively (Figure 23) (p>0.05).  This 
suggests that the two drugs are not interacting in a manner that affects their release 
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from the liposomes and the synergistic ratios of doxorubicin and irinotecan were 
adequately maintained after 72 hours.  Also, it is noteworthy to understand that the 
liposomes prepared with Cu2+ gradient released greater amount of both drugs as 
compared to those prepared with Mn2+, particularly for irinotecan (p < 0.05) during 
the course of study (Figure 23).  This could be due to the known ability of copper to 
interact with the phospholipid membranes of liposome and thereby altering its 
permeability (Khomutov, Yakovenko et al. 1997; Suwalsky, Ungerer et al. 1998; 
Lebedev, Volodina et al. 2005).  The ability of copper to increase permeability of 
DSPC/cholesterol liposome has been reported recently in a study, where a comparison 
on retention of sucrose using saline based and copper sulphate based liposome were 
conducted, and the outcome of the study suggested that liposome prepared using 
copper sulphate enhanced membrane permeability and thereby decreased sucrose 
retention as compared to that of saline containing liposome (Patankar, Anantha et al. 
2011).  When the liposome hydrated with ferrous sulphate tested for in vitro release, it 
was observed that the release pattern of doxorubicin in the co-encapsulated 
formulation (Figure 23) did not differ substantially from that in the individually-
loaded liposomes (Figure 23) (p> 0.05).  However, the release rate of irinotecan in the 
co-encapsulated liposomes (Figure 23) was significantly different from the drug 
release rate in the individually-loaded liposomes (Figure 23) (p<<0.05); irinotecan 
leaked out of the liposomes at a notably greater rate in the co-encapsulated 
formulation as compared to doxorubicin.  As a result, at the end of 72 hours, the 
synergistic ratio of doxorubicin: irinotecan changed significantly from desired 1:1 
ratio (p< 0.05) (Figure 24).  This trend of increased leakage of drugs from FeSO4 
liposomes may be possibly due to the peroxidation of lipid bilayers caused by ferrous 
ions, which could have consequently led to changes in the permeability of lipid 
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bilayers.  A study has been reported where peroxidation of lipid bilayers caused by 
ferrous sulphate resulted in increased liposomal permeability of glucose (Kunimoto, 
Inoue et al. 1981).  However, it must be noted that only irinotecan was released 
rapidly from the FeSO4 based co-encapsulated liposomes, whereas doxorubicin was 
well retained (Figure 23). Thus, if increased liposomal permeability initiated by 
ferrous sulphate is considered as a probable reason for rapid release of irinotecan from 
FeSO4 based co-encapsulated liposome; it is unclear why it did not caused rapid 
release of doxorubicin. Thus, there might be other factors responsible for rapid release 
of irinotecan and needs to be investigated further. 
Stability studies were conducted on copper (with or without ionophore 
A23187) and manganese with ionophore A23187 containing liposome preparations as 
they exhibited desired loading and release characteristics.  Stability was evaluated 
based on the encapsulated drug content remaining in the liposomes and the size of 
liposomes when refrigerated at 4ºC for 8 weeks.  Liposomes were stored at 4ºC as 
physical instability of liposomes had been demonstrated to increase sharply when 
storage temperature increased from 4ºC to 25ºC (du Plessis, Ramachandran et al. 
1996).  Results gathered at the end of 8 weeks showed that stability of the liposomes 
in terms of drug retention was comparable, irrespective of whether Cu2+ gradient was 
employed in the presence or absence of A23187 with around 65 % of irinotecan and 
70 % of doxorubicin still retained  (Figure 25) (p> 0.05).  On the other hand, 
liposomes containing Mn2+ gradient showed comparatively superior drug retention 
and stability of the liposome by size, with around 95 % of both drugs still retained in 
the liposome at the end of 8 weeks (p< 0.05) (Figure 25).  Since manganese 
containing liposomes were found to be superior in terms of drug retention over 8 
weeks, further investigation of the physical stability over a longer period of time (i.e. 
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24 weeks) was carried out for this particular formulation to provide a more insightful 
conclusion.  After storage for 24 weeks, it was observed that around 90% of the 
encapsulated drug content was still retained in the liposomes, with the drug/drug 
molar ratio of 1:1 being maintained (Figure 26).  In addition, the size and 
polydispersity of manganese containing liposomes after 24 weeks of stability study 
were not significantly different than that of week at the start of the study (p> 0.05) 
(Figure 26).  Since the co-encapsulated liposome formulation prepared using 
manganese sulphate plus A23187 demonstrated efficient drug encapsulation 
efficiency, desired release profile and superior stability as compared to other 
liposomal preparations tested (p< 0.05); it was considered as a potential lead 
formulation for further development (Table 9).  Further characterization of the MnSO4 
+ A23187 co-encapsulated liposome included the changes in loading sequence, 
loading using chloride as anion, loading at different drug-to-lipid molar ratio, 
determining the residual liposomal manganese determination, loading at increased 
lipid concentration, loading of different drug: drug ratios , morphology of the MnSO4 
+ A23187 co-encapsulated liposome, its comparison with single loaded liposome 
using cryo-TEM and finally release and stability testing of liposome containing high 
Mn2+ core (600 mM).    
The loading efficiency of the two drugs displayed a gradual decrease in the 
final drug-to-lipid molar ratio over the 180-min time course, when the two drugs were 
added simultaneously or when the order of addition was reversed (Figure 27).   As 
showed earlier (Figure 19 and 20) irinotecan could be loaded into the manganese 
based liposomes only in presence of the pH gradient generated by ionophore A23187.  
Thus, the instability observed in the liposomes where irinotecan and ionophore is 
added prior to doxorubicin, could be due to the disruption of the ionophore generated 
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transmembrane pH gradient by doxorubicin.  This effect of doxorubicin on dissipation 
of pH gradient is not surprising.  In fact, it has been demonstrated that doxorubicin 
addition to the liposomes prepared using acidic citrate, manganese sulphate or 
manganese chloride (all adjusted to pH 3.5) resulted in rapid dissipation of the 
transmembrane pH gradient (Abraham, Edwards et al. 2002).  These data suggest that 
sequential loading of doxorubicin followed by irinotecan is essential for efficient 
loading and stable retention of both the drugs into the liposome.  Next, co-
encapsulation of doxorubicin and irinotecan into the liposomes using manganese 
chloride resulted in gradual decrease of both the drugs over the time period of 180 
min during drug loading (Figure 28), indicating that the presence of sulphate ion was 
essential for stable loading of the two drugs.  This poor retention of the two drugs 
could be due to the fact that manganese chloride + ionophore system generates pH 
gradient (around 1.8), which is comparatively lower than that generated by manganese 
sulphate + ionophore (around 4.0) (Abraham, Edwards et al. 2002).  Similar gradual 
decrease in drug loading efficiencies of liposomes is being reported for drugs such as 
mitoxantrone and doxorubicin, when sulphate containing hydration salts are replaced 
by chloride containing salts (Li, Cui et al. 2008; Abraham, Edwards et al. 2002).  
In order to determine the maximum level of co-encapsulation of doxorubicin 
and irinotecan achievable using the current loading conditions, we evaluated the effect 
of incrementally increasing the drug-to-lipid molar ratio from 0.1:1 to 0.3:1 on drug 
encapsulation.  More than 95 % of both the drugs were efficiently loaded in to the 
liposomes with drug-to-lipid molar ratio of 0.1:1 and 0.2:1 (Figure 29).  However, a 
sharp decrease in encapsulation efficiency of the two drugs was observed with drug-
to-lipid molar ratio of 0.3:1 (Figure 29), with loading efficiencies of 70% and 80% for 
irinotecan and doxorubicin respectively. This decrease in encapsulation could be due 
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to insufficient Mn2+ ions available for the complexation with doxorubicin and the 
subsequent generation of the pH gradient via ionophore for the loading of irinotecan.  
Thus, to investigate whether the deficiency of Mn2+ ions resulted in poor 
encapsulation at drug-to-lipid molar ratio of 0.3:1, the intraliposomal MnSO4 
concentration was varied in the concentration range of 150 mM to 750 mM (in the 
presence of ionophore) and its impact on drug loading was evaluated.  Interestingly, 
the total drug-to-lipid molar ratio that could be encapsulated in liposomes increased 
with increase in MnSO4 concentration and a linear relationship between the total 
drug-to-lipid molar ratio encapsulated in to the liposome and intraliposomal Mn2+ 
concentration was observed (Figure 30).  Moreover, the results suggested that a 
maximum drug-to-lipid molar ratio of 0.9:1 could be achieved using 750 mM MnSO4 
(Figure 30), which is very good from formulation development perspective as it 
allows to prepare concentrated liposome preparations just by making use of high 
concentration of hydration medium. This has great significance when high dose drugs 
needs to be loaded into the smaller volume of liposomes for subsequent use in 
preclinical/clinical studies.  In addition, as toxicity concerns could be raised for Mn2+, 
it became essential to estimate the residual amount of Mn2+ ion left entrapped into 
MnSO4 + A23187 liposome and was found to be well below the toxic levels and 
appear to pose no safety risk (Table 10).  Moreover, there are several Mn2+ containing 
magnetic resonance (MR) contrast agents that are under use at doses relatively higher 
than that present in these liposomal preparations and have shown no major toxicity 
concerns after use (Unger, Shen et al. 1991; Crossgrove and Zheng 2004). 
The effect of increasing the lipid concentration from 5 µmol/ml to 10 µmol/ml 
on drug loading efficiencies demonstrated that the drug loading for both the drugs can 
be effectively carried out at higher lipid concentrations (Figure 31).  This is of great 
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importance from manufacturing perspective where high pay load of drugs in lesser 
volume of liposome is desired.  As discussed earlier in Chapter 1, synergism could 
only be achieved if the various agents exist at particular concentration ratios at the site 
of action.  Moreover, it becomes more important that these two drugs reach the target 
site in the desired synergistic ratio.  In the present study, we found 1:1 ratio being 
synergistic when tested using three different ovarian cancer cell lines (IGROV-1, 
SKOV-3 and OVCAR-3).  However, there may be other potential doxorubicin: 
irinotecan molar ratio which could be effective in cancer cell lines other than ovarian 
cancer, thus useful in treatment of other types of cancers and can be explored in 
future.  Hence, we thought it would be interesting to evaluate 1) whether the current 
formulation is capable of incorporating doxorubicin: irinotecan molar ratio other than 
1:1 (we selected 1:10 and 10:1), and 2) to see if one drug would interfere the loading 
of another when a larger drug/drug ratio is to be encapsulated.  As shown in Figure 
32, both the drugs could be effectively loaded in to the liposome with more than 80% 
encapsulation efficiency.  This is an encouraging outcome and indicated that there is 
no interaction within the drugs when co-encapsulated into the single liposome, even at 
higher drug: drug molar ratios and most importantly that the current formulation is 
capable of co-encapsulating drug ratios other than 1:1.  The cryo-TEM images 
revealed that the intraliposomal drug precipitate for MnSO4 + A23187 liposome was 
without a defined structure (Figure 33).  Even the liposome prepared without A23187, 
showed similar images with the lack of defined structure and the intraliposomal drug 
precipitate was comparatively smaller in amount (Figure 33).  The observations in 
cryo-TEM images of the intraliposomal drug precipitate for formulation with and 
without ionophore goes well with the results obtained from our drug loading 
experiments for these two formulations (Figure 19 and 20), where we found that 
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around 100 % of both doxorubicin and irinotecan could be loaded in MnSO4 + 
A23187 liposome (larger intraliposomal drug precipitate), whereas only 20 % and 55 
% of irinotecan and doxorubicin respectively could be encapsulated in MnSO4 - 
A23187 (smaller intraliposomal drug precipitate).  Finally, the liposomes containing 
high Mn2+ core (600 mM) with drug-to-lipid molar ratio of 0.4/1 of each doxorubicin 
and irinotecan was subjected to release study and was found to provide controlled 
release with desired stability characteristics (Figure 34 and 35).  This high Mn2+ core 
liposomal formulation with high drug pay-load was used for animal studies 















4.3 Simultaneous determination of doxorubicin and irinotecan along with their 
major metabolites, doxorubicinol and SN38 using ultra high performance liquid 
chromatography 
 
4.3.1 Section overview 
Doxorubicin (Adriamycin) is a cytotoxic anthracycline antibiotic isolated from 
cultures of Streptomyces peucetius var. caesius (Sullivan, Michael et al. 1987).  
Doxorubicin is rapidly metabolized by the cytoplasmic NADPH-dependent aldo-keto 
reductase to the secondary alcohol metabolite, doxorubicinol, and by the NADPH 
dependent cytochrome P450 reductase to a broad panel of hydroxy- or deoxy-
aglycones (Minotti, Ronchi et al. 2001).  Doxorubicin and its major metabolite 
predominantly get excreted through the bile (Takanashi and Bachur 1976).  Irinotecan 
hydrochloride (CPT-11) is a semi synthetic derivative of camptothecin (CPT).  
Following in vivo administration, irinotecan is hydrolyzed by carboxylesterases 
(mainly found in liver) to its active metabolite SN 38 (7-ethyl-10-
hydroxycamptothecin). SN 38 is highly insoluble and hence administered as a 
prodrug, irinotecan.  SN38 possesses activity that is thousand times more potent than 
irinotecan.  SN 38 is further converted to SN38G by uridine diphosphate glucuronosyl 
transferases 1A and 1A9, which is eliminated by biliary excretion (Santos, Zanetta et 
al. 2000).  Both irinotecan and SN38 has an active lactone form and inactive 
carboxylate form.  Several high performance liquid chromatography (HPLC) methods 
with either mass spectrometry or fluorescence spectrometry as detectors have been 
developed for simultaneous determination of doxorubicin and its metabolites in 
various kind of biological matrix such as plasma, serum, saliva and tissue 
homogenates (Katzenmeyer, Eddy et al. 2010; Maudens, Stove et al. 2008; Maudens, 
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Stove et al. 2009; Gotlieb, Bruchim et al. 2007; Arnold, Slack et al. 2004).  Similarly, 
HPLC methods with either mass spectrometry, ultraviolet spectrometry or 
fluorescence spectrometry as detectors have been developed to quantify irinotecan 
and its major metabolites in presence of plasma, saliva, serum, urine, feces and tissue 
homogenates (Bansal, Awasthi et al. 2008; Hu, Yang et al. 2007; Yang, Hu et al. 
2005; Bardin, Guo et al. 2005; Poujol, Pinguet et al. 2003; Schoemaker, Rosing et al.  
2003; Sparreboom, de Brujin et al. 1998) 
Recently, doxorubicin and irinotecan have gained a lot of interest as a drug 
combination under clinical settings, for the treatment of ovarian carcinoma, solid 
tumors, and lung cancer (Nishimura, Tsuda et al. 2007; Morgensztern, Baggstrom et 
al. 2009; Xenidis, Vardakis et al. 2010).  The present study of ours also involves co-
encapsulated liposome containing doxorubicin and irinotecan for treatment of ovarian 
carcinoma.  To date, no published method is available to determine doxorubicin and 
irinotecan simultaneously in the plasma along with their major metabolites. Hence, 
there is a need to develop and validate a sensitive and specific chromatographic 
method to simultaneously quantify these two drugs along with their major metabolites 
from plasma samples.  This would help in detection of these two compounds from 
either mice/rat plasma sample (preclinical testing) or patient plasma samples (clinical 
testing)  in a single run and thereby assist determination of the pharmacokinetic 
parameters in various ongoing preclinical and clinical trials, which are being 
conducted using these drug cocktails for treatment of various types of cancer.  Thus, 
development of a UPLC-based analytical method for simultaneous determination of 





4.3.2 Section Results 
4.3.2.1 Optimization of Liquid chromatographic conditions  
 In order to obtain desired resolution, high specificity and sensitivity, trials 
using different gradient elution programmes were carried out. A detailed description 
about the chromatographic conditions used is discussed in Chapter 3, section 3.10.  
A mixture of doxorubicinol, irinotecan, doxorubicin, SN 38 and internal 
standard camptothecin was subjected to gradient elution.  To reduce peak tailing, 
0.1% (v/v) formic acid was added to both the aqueous (distilled water) and organic 
(acetonitrile) mobile phase. Gradients that have been attempted ranged from Mode 1] 
90% aqueous (0-2 min) followed by 80% aqueous (2-3 min) and finally back to 90 % 
aqueous (3-5 min), Mode 2] 88% aqueous (0-2min) followed by 75% aqueous (2-3 
min) and finally back to 88 % aqueous (3-5 min) , Mode 3] 85% aqueous (0-1min) 
followed by 70% aqueous (2-3 min) and finally back to 85 % aqueous (3-5 min) , 
Mode 4] 80% aqueous (0-1min) followed by 70% aqueous (2-3 min) and finally back 
to 80 % aqueous and Mode 5] 85% aqueous (0-1min) followed by 70% aqueous (1-4 
min) and finally back to 85 % aqueous (4-7 min).  Broadening of analyte peaks were 
observed while using mode 1, 2 and mode 3. Narrow peak shape and desired elution 
was observed for mode 4, however; the internal standard could not be eluted using the 
gradient conditions in this mode.  Mode 5 was found to be optimal gradient and 
showed good resolution and narrow peak shapes for all the analytes and internal 
standard (Figure 36). The retention time of doxorubicinol, irinotecan, doxorubicin, 
SN38 and camptothecin (internal standard) using mobile phase solvent was found to 
be 2.065, 2.174, 2.470, 3.059, and 3.629 minutes respectively. Total run time was kept 
as 7 minutes.   Doxorubicin, irinotecan and their metabolites, doxorubicinol and 
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SN38, were detectable, and their peaks were well separated from each other. This 










Figure 36: (A) Representative chromatogram of analytes along with the internal standard. 1. 
doxorubicinol, 2. irinotecan, 3. doxorubicin, 4. SN38 and 5. Camptothecin/CPT (internal 










4.3.2.2 Method Validation 
The validation of the analytical method was done according to the standard 
procedures based on FDA guidance (Bansal and DeStefano 2007; 




1. Specificity in plasma samples 
We investigated the specificity of the method by comparing the retention times 
of endogenous substances from mice plasma to that of the compounds of interest.  
Figure 37 show representative chromatograms of blank mice plasma and mice plasma 
spiked with the doxorubicinol, irinotecan, doxorubicin, SN38 and camptothecin 
(internal standard) at 254 nm.  As can be seen there was no peak from the blank 
plasma matrix that interfered with any of the aforementioned analytes and internal 
standard demonstrating high specificity of the method for the compounds of interest.  
The retention times of doxorubicinol, irinotecan, doxorubicin, SN38 and 
camptothecin (internal standard) were found to be 2.106, 2.216, 2.516, 3.105, and 














Figure 37: Representative chromatograms of A) blank mice plasma B) mice plasma spiked 
with known amounts of analytes spiked along with the internal standard. 1. doxorubicinol, 2. 

















2.  Linearity in plasma samples 
The average calibration equation relating y (peak area ratio of drug: internal 
standard) to x (nominal concentration) was plotted from three analytical runs at seven 
different concentrations.  The metabolites are normally present in lower concentration 
when compared to their parent compounds and thus doxorubicinol and SN 38 were 
spiked in the mice plasma at concentration half of doxorubicin and irinotecan 
concentration. The concentration range for calibration standard curve of irinotecan 
and doxorubicin were 250 ng/ml to 10,000 ng/ml and 125 ng/ml to 5000 ng/ml for 
doxorubicinol and SN38.  The linearity of the assay procedure was determined by 
calculation of regression line using the method of unweighted least square analysis. 
As evident from the coefficient of correlation (r), the calibration graphs were linear, 
for irinotecan, doxorubicin, doxorubicinol and SN-38 in the concentration ranges 
assayed; 250 ng/ml to 10,000 ng/ml and 125 ng/ml to 5000 ng/ml. The slopes and 
intercepts were consistent throughout the different sets of analytical runs and are 
listed in Table 11.   
Table 11: Linearity of analytes in mice plasma samples. The calibration curve was a seven 
point curve. 
 





0.0886 ± 0.0006 0.00246 ± 0.0006 0.9984 
irinotecan 250-10,000 
ng/ml 
0.0927 ± 0.0006 0.00527 ± 0.0005 0.9989 
doxorubicinol 125-5,000 
ng/ml 
0.0656 ± 0.0005 0.00037 ± 0.0002 0.9959 
SN38 125-5,000 
ng/ml 
0.0723 ± 0.0005 0.00040 ± 0.0006 0.9985 
 
a Values are mean±S.D. of three calibrations. 
b r is the correlation coefficient obtained from seven-point calibration curve. The concentrations across 






3.  Limit of quatitation and detection in plasma samples 
         The limit of quantification (LOQ) was defined as the lowest drug 
concentration that could be determined with acceptable precision (i.e., C.V. < 20%) 
and accuracy (i.e., recovery 100±20%). The limit of detection (LOD) was defined as 
the amount, which could be reliably differentiated from the background noise. The 
detection limit was determined by the analysis of samples with known concentrations 
of analyte and by establishing the minimum level at which the analyte could be 
reliably detected. The LOQ for irinotecan was 250 ng/ml (accuracy: 106 ± 6%; C.V: 
5.9%), doxorubicin was 250 ng/ml (accuracy: 103 ± 4%; C.V: 5.9%), and for SN-38 
(accuracy: 101 ± 3%; C.V: 3.4%), doxorubicinol was 125 ng/ml (accuracy: 87 ± 2%; 
C.V: 2.3%), (n=5). The detection limits were 175 ng/ml for irinotecan, 150 ng/ml for 
doxorubicin, and 90 ng/ml doxorubicinol and 75 ng for SN-38, respectively (n=5). 
 
4. Accuracy and precision in plasma samples 
The accuracy and precision data are shown in Table 12. Quality control (QC) 
samples for each analyte were prepared in triplicate at three different concentrations 
viz. low (LQC), medium (MQC) and high (HQC) from weighing independent of those 
used for preparing calibration curves. Both accuracy (recovery±15%) and precision 
(<5% C.V.) was found to be suitable and do not depend on the concentration assayed 

























doxorubicin 750 ng/ml 710 94.66 4.18 730 96.64 4.80 
3750 ng/ml 3830 102.2 0.30 3700 98.61 2.49 
7500 ng/ml 8100 108.0 2.42 7420 98.96 3.79 
irinotecan 750 ng/ml 730  97.71         2.11 720 95.78 1.61 
3750 ng/ml 3780 100.8 0.40 364 97.42 3.66 
7500 ng/ml 7930 105.7 1.89 7460 99.19 3.11 
doxorubicinol 375 ng/ml 360 95.06 1.54 341 90.93 3.67 
1880 ng/ml 1890 100.5 1.39 1910 101.91 2.52 
3750 ng/ml 4000 106.6 1.98 3670 98.08 3.09 
SN38 375 ng/ml 330 88.71 2.55 332 89.65 4.90 
1880 ng/ml 1990 106.0 1.15 1940 103.61 3.13 
3750 ng/ml 3520 94.0 0.71 3620 96.48 4.91 
 
 
a Selected concentrations represent the low, medium and high quality control concentrations viz. LQC, 
MQC and HQC. Intra-day and inter-day accuracy and precision was determined with replicates (n = 5) 
for each concentration. C.V. (coefficient of variation) = (S.D./mean)×100. 
 
5. Extraction efficiency  
The overall plasma extraction recovery for the four analytes (irinotecan, 
doxorubicin, doxorubicinol and SN-38) and internal standard (camptothecin) was 
determined by comparing the absolute peak areas of the QC samples in plasma with 
those obtained from neat solutions (unextracted). Protein precipitation technique was 
found to be effective and efficient recoveries with acceptable C.V. of all the analytes 







Table 13: Extraction efficiency of QC samples (low, mid, and high) in mice plasma samples.  
 
Analyte Nominal concentrationa % Extraction efficiency C.V. 
doxorubicin 750 ng/ml 103.30 3.85 
3750 ng/ml 98.21 0.24 
7500 ng/ml 108.71 2.40 
irinotecan 750 ng/ml 101.12         2.04 
3750 ng/ml 98.82 1.58 
7500 ng/ml 108.79 1.91 
doxorubicinol 375 ng/ml 91.0 1.44 
1880 ng/ml 95.3 1.40 
3750 ng/ml 109.73 1.88 
SN38 375 ng/ml 113.91 1.84 
1880 ng/ml 93.16 0.91 
3750 ng/ml 93.36 0.72 
 
a Selected concentrations represent the low, medium and high quality control concentrations viz. LQC, 
MQC and HQC. Extraction efficiency was determined with triplicates (n = 3) for each concentration. 
C.V. (coefficient of variation) = (S.D./mean)×100. 
 
6. Stability in plasma samples 
The stability of the four analytes (irinotecan, doxorubicin, doxorubicinol and 
SN-38) in plasma samples was found to be satisfactory (Table 14). 
Table 14: Stability of QC samples in mice plasma samples at 4ºC for 24 h.  
 
Analyte Nominal concentrationa Measured concentration 
Mean C.V. 
doxorubicin 750 ng/ml 724 5.99 
3750 ng/ml 3773 1.33 
7500 ng/ml 7466 0.47 
irinotecan 750 ng/ml 711 3.71 
3750 ng/ml 3646 0.88 
7500 ng/ml 7396 0.66 
doxorubicinol 375 ng/ml 335 4.13 
1880 ng/ml 1892 1.3 
3750 ng/ml 3710 0.14 
SN38 375 ng/ml 343 1.31 
1880 ng/ml 1834 0.37 
3750 ng/ml 3661 1.26 
 
a Selected concentrations represent the low, medium and high quality control concentrations viz. LQC, 
MQC and HQC. Stability of samples were determined with triplicates (n = 3) for each concentration. 




4.3.3 Section discussion 
 
As mentioned earlier, there have been no reported analytical methods that can 
be used to simultaneously detect doxorubicin, irinotecan and their respective major 
metabolites and therefore it is necessary to develop and validate method to quantify 
the said analytes from murine plasma samples.  Method development was carried out 
based on the guidelines listed by FDA.  Under these guidelines, the lower limit of 
quantitation (LLOQ) standard back-calculated concentrations must be within ±20% of 
theoretical nominal concentrations and all other standards’ back-calculated 
concentrations must be within ±15% of their nominal theoretical concentrations.  For 
precision, the values should not exceed 15% CV except at LLOQ, where it should not 
exceed 20% CV. Extraction recoveries must be consistent. Moreover, the method 
developed should be selective for the analytes under consideration and sensitive 
enough to determine the prospective samples from pharmacokinetic studies. 
Effective separation of analytes was possible using a simple mobile phase 
composition containing distilled water: acetonitrile with 0.1 % v/v formic acid. The 
chromatographs of the blank plasma showed that there was no interference with the 
endogenous substances. The method demonstrated good calibration fit, precision, 
accuracy and good extraction efficiency.  In addition, the mean values and the CV% 
values obtained during method validation conformed to FDA guidelines. This method 
will be applied to analyze the plasma drug concentration from murine samples 





4.4 Pharmacokinetic profile and therapeutic efficacy of liposomes co-
encapsulating doxorubicin and irinotecan 
 
4.4.1 Section overview 
In section 4.2, 600 mM MnSO4 + A23187 based liposomes were shown to co-
encapsulate irinotecan and doxorubicin effectively at high drug-to-lipid molar ratio, 
displayed sustained and coordinated release of both these drugs in vitro, and desired 
stability characteristics.  However, in order to ultimately transform a potential 
formulation from lab to clinic, it is essential to demonstrate the in vivo performance of 
the developed co-encapsulated liposomal formulation and compare it with 
conventional aqueous saline based drug cocktail formulation.  First, it is important to 
select suitable route through which the formulations could be injected as different 
route of administration has different impact on in vivo performance of drug substance 
and/or formulations. For the treatment of ovarian cancer both intraperitoneal and 
intravenous routes of administration are widely used.  The advantages offered by 
intraperitoneal route are reduced systemic side effects and higher local drug 
concentration (Guarneri, Piacentini et al. 2010).  However, intraperitoneal route 
suffers from treatment-related complications such as bowel perforations, abdominal 
discomfort, and nausea, leading to patient non-compliance (Guarneri, Piacentini et al. 
2010).  On the other hand, such side effects are not observed with intravenous 
administration (Bally, Masin et al. 1994).  Moreover, the current clinical practice does 
place emphasis on use of intravenous administration over intraperitoneal 
administration.  Therefore, in the present study, intravenous was chosen as a route of 
choice for administration of irinotecan and doxorubicin, both in free and liposomal 
form. The present section discusses the in vivo data generated from (1) the plasma 
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elimination profiles of the free drug cocktail with co encapsulated liposomal 
formulation, and (2) the antitumor efficacy of the free drug cocktail with co-
encapsulated liposomal formulation in a IGROV-1 tumor bearing mice model. 
 
4.4.2 Section Results 
4.4.2.1 Plasma elimination profiles of co-encapsulated liposomal formulation 
versus saline based free drug cocktail of doxorubicin and irinotecan 
The plasma elimination profiles of free versus liposomal encapsulated 
doxorubicin and irinotecan (dose: 10 micromole/kg for both the drugs) were 
determined in female Balb/c mice (20-22g).  As can be seen in Figure 38, free 
doxorubicin and irinotecan could not be detected in the plasma after 30 minutes.  On 
the other hand, the levels of doxorubicin and irinotecan could still be detected in the 
group of mice treated with liposomes for 24h duration of the entire study.  In addition, 
doxorubicin and irinotecan in liposomes were found to demonstrate longer half lives, 
higher maximal concentration in plasma, higher total area under the curve, higher 
mean residence time and lower clearance as compared to the free drug combination 
(Table 15).  Moreover, Figure 39 shows that the liposomal formulation was effective 
in maintaining the synergistic 1:1 molar ratio of doxorubicin: irinotecan.  In contrast, 
the doxorubicin: irinotecan ratio of 1:1 could not be maintained by the saline based 














Figure 38: Concentrations of irinotecan and doxorubicin in Balb/c mice plasma after 
intravenous administration of (A) liposomes co-encapsulating irinotecan and doxorubicin and 
(B) free drug cocktail of irinotecan and doxorubicin. Concentrations of irinotecan are 











































































Table 15: Summary of pharmacokinetic parameters for irinotecan and doxorubicin as free 















0.0049 0.0018 0.124 0.143 
Tmax (h) 0.083 0.083 0.5 0.5 
Cl (ml/h) 105.47 300.56 0.220 0.233 
Vd (ml) 23.51 80.50 1.018 1.014 
AUC l a s t 
(μmol.h/mL) 
0.0017 0.0005 0.903 0.852 
T 1/2 (h) 0.154 0.202 3.09 3.05 
MRT l as t (h) 0.171 0.153 4.537 4.251 
r 0.931 0.950 0.993 0.998 
 
Mice (n=3) received the free combination of 10µmol/kg of each irinotecan and 
doxorubicin (1:1 doxorubicin/irinotecan mole ratio) or 10µmol/kg of each irinotecan 
and doxorubicin (1:1 doxorubicin/irinotecan mole ratio) co-encapsulated into 
liposomes.  Pharmacokinetic parameters were obtained from the pooled data from 3 
mice. Cmax: Maximum plasma concentration of drug, t max: Time taken to attain 
maximum plasma concentration, AUC last: Area under the curve computed to the last 
observation, t1/2: half life, Cl: total body clearance, MRT last: Mean residence time up 







Figure 39: Comparison of the molar ratio of irinotecan and doxorubicin over time for (A) 
irinotecan /doxorubicin in co-encapsulated liposomes (♦) and (B) irinotecan /doxorubicin in  
free drug cocktail (■) when tested in Balb/C mice. The dotted line represents the initial ratio 
of irinotecan and doxorubicin. Each value represents the mean ± SEM from 3 samples.  The 
molar ratio of irinotecan: doxorubicin varied significantly from desired ratio 1:1 in free drug 

























































4.4.2.2 In vivo antitumor efficacy study against human IGROV-1 ovarian tumor 
xenograft model 
The antitumor efficacy against the IGROV-1 tumor bearing mouse model was 
evaluated by comparing (1) vehicle control (0.9 % saline), (2) Free drug cocktail 
containing doxorubicin: irinotecan mixed in molar ratio of 1:1 diluted in 0.9 % saline, 
and (3) Co-encapsulated  liposome formulation containing doxorubicin: irinotecan in 
molar ratio of 1:1.  The dose administered was 10 µmol/kg for doxorubicin and 
irinotecan (molar ratio of 1:1), which corresponded to two-thirds of the maximum 
tolerated dose (MTD) of doxorubicin, and one-tenth of MTD of irinotecan.  Kaplan–
meier survival analysis with log-rank test was conducted, and the results are shown in 
Figure 40.  Statistical significance (p<0.05) was found in the co-encapsulated 
liposomal formulation against the vehicle control (0.9 % saline) and against free drug 
cocktail group.  Increase in life span was found to be 93% for the group treated with 
co-encapsulated liposomal doxorubicin and irinotecan (Table 16). Moreover, 
percentage weight change at nadir was used as the indicator of the toxicity of the 
treatment (Laster, Schable et al. 1961).  The percentage weight change at nadir for 
free drug cocktail of doxorubicin and irinotecan group was found to be statistically 
greater (p<0.05) than that of the co-encapsulated liposome treatment group, indicating 
high incidence of toxicity for free drug cocktail when compared to the liposomal 
group (Figure 41).  This increased toxicity effect from free drug cocktail is likely due 
to the combined effect of the two drugs on the normal proliferating cells in the GI 
tract and hematopoetic system.  Dry weight of excised spleen was also monitored as it 
is often associated with the state of disease progression in mice (Elsayes, Narra et al. 
2005; Overman, Maru et al. 2010).  As can be seen in Figure 42, 4-fold increase in 
spleen weight (p< 0.05) was observed for mice treated with the saline group when 
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compared to that of normal mice (no tumor and no treatment).  On the other hand, 
mice under free drug cocktail group showed decrease in spleen weight.  High 
exposure of the drug to the spleen and subsequent toxicity might have resulted in 
reduced spleen weight in mice receiving free drug cocktail.  Decrease in mice spleen 
weight due to topoisomerase inhibitors treatment in their free form is consistent with 
other reported studies (Verdrengh and Tarkowsi 2003; Lopez, Zhang et al. 2004).  For 
mice treated with the co-encapsulated liposomal formulation, the increase in spleen 
weight compared to that of normal mice was insignificant.   
 
 
Figure 40:  Kaplan-Meier survival curves of the different treatment groups over time (n=5), 
0.9% saline (control)   , free drug cocktail containing doxorubicin: irinotecan (1:1) molar 
ratio  and liposomal formulation co-encapsulating doxorubicin: irinotecan (1:1) 













Table 16: Increase in life span of mice treated with different treatment groups   
 
Formulation Drug dose 
(µmol/Kg) 
Molar ratio of 
doxorubicin to 
irinotecan 
% Long term 










Saline NA NA 0 % 27.0 NA 




10 1:1 25 % 52.0 93 
*% Increase in life span (ILS) is calculated as [treatment group- control group/control group] 
x 100. Statistically significant difference was observed for co-encapsulated liposomal 
preparation when compared with free drug cocktail and saline (control) groups (p < 0.05).  
 
 
Figure 41: Changes in body weight of mice between different treatment groups (◆Saline 
group, ∎ free drug cocktail, and ▲ co-encapsulated liposome group). Statistically significant 
difference was observed for co-encapsulated liposomal preparation when compared with free 
drug cocktail group (p < 0.05).     
 
 
Figure 42: Changes in dried spleen weight of mice between different treatments groups (1. 
saline group, 2. free drug cocktail, 3. co-encapsulated liposome group and 4. normal healthy 
mice (no tumor inoculation and no treatment). Statistically significant difference was 
























































4.4.3 Section Discussion 
In this section, the in vivo performance of free doxorubicin: irinotecan cocktail 
is compared to that of liposomal co-encapsulated doxorubicin/irinotecan formulation 
following intravenous injections.   
The results presented herein demonstrate the co-encapsulation of doxorubicin 
and irinotecan into a liposomal preparation resulted in sustained and synchronized 
release of both drugs, maintaining the desired 1:1 molar ratio of drugs in vitro as well 
as in vivo.  On the other hand, the administration of doxorubicin and irinotecan as free 
drug cocktail failed to maintain the desired synergistic ratio and exhibited 
pharmacokinetic profiles expected from free drug administration which assumed 
significantly lower systemic exposure.  These data demonstrated the significance of 
having a suitable drug carrier to deliver the drug combination in a synergistic ratio in 
vivo and subsequently at the tumor site.   
Consistent with previous studies, the current pharmacokinetic studies showed 
that free doxorubicin and free irinotecan had short half lives (Gustafson, Rastatter et 
al 2002; de Jonge, Verweij et al. 2000).  After liposomal encapsulation, the in vivo 
half-life of doxorubicin and irinotecan increased by about 20 and 15 folds, 
respectively, when compared to free doxorubicin and irinotecan (Table 15).  
Moreover, prolonged exposure of topoisomerase inhibitors could result in extended 
co-exposure of drugs at the tumor site and thereby can lead to enhanced therapeutic 
activity. The higher C max, T max, AUC last, MRT last and lower Cl is also consistent 
with prior studies involving liposomes as carrier for these drugs (Waterhouse, Tardi et 
al. 2001, Ramsay, Anantha et al. 2008).  It was observed that C max increased by 25 
folds for doxorubicin and 80 folds for irinotecan, when co-encapsulated into 
liposomal formulation. This many folds increase in C max could increase the drug 
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concentration at the tumor site and thereby enhance the therapeutic activity of the 
liposomal preparation.  In addition, the Vd was found to be reduced considerably for 
doxorubicin and irinotecan when co-encapsulated in liposomal formulations. This 
decrease in Vd, could result in reduced exposure of drugs to the normal body tissues 
and thereby can cause reduced incidence of drug related adverse toxic side effects. 
Finally, liposomal encapsulation also maintained the optimal synergistic 
doxorubicin: irinotecan molar ratio of 1:1 in plasma over entire period of study.  The 
ability of liposome to synchronize the release of drugs in plasma in their respective 
synergistic ratio has also been demonstrated in various other reported studies for 
different types of drugs (Tardi, Johnstone et al. 2008; Tardi, Dos Santos et al. 2009).   
In addition of maintaining the synergistic ratio and offering desired 
pharmacokinetic properties, the liposome formulation co-encapsulating doxorubicin 
and irinotecan also demonstrated enhanced antitumor efficacy, even at two-thirds and 
one-tenth of the maximum tolerated dose (MTD) of doxorubicin and irinotecan 
respectively, highlighting the therapeutic potential of this formulation. 
Among the three different treatment groups, the best antitumor activity was 
shown by the group of mice treated with liposome co-encapsulating doxorubicin and 
irinotecan as reflected in the survival data.  Taking the pharmacokinetic data together, 
the increased antitumor efficacy in the co-encapsulated liposome group could be 
attributed to (1) the longer half life of doxorubicin and irinotecan, which consequently 
increased the duration to which the tumor is exposed to both drugs resulting in 
enhanced antitumor activity, and (2) the optimal synergistic ratio of doxorubicin: 
irinotecan was maintained in the plasma.  Most importantly, this formulation showed 
promising antitumor activity in vivo even at two-thirds of the maximum tolerated dose 
(MTD) of doxorubicin and one-tenth of the maximum tolerated dose (MTD) of 
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irinotecan, which demonstrated the potential of this formulation to achieve antitumor 
efficacy while reducing the dose related adverse side effects, which ultimately will 
result in increased therapeutic index.  Kaplan-meier survival analysis with log rank 
significance test was conducted to determine if there was any statistical difference in 
survival among the different groups.  The log rank significance test showed that there 
was statistical difference between (1) the free doxorubicin/irinotecan combination 
group and (2) the liposomal co-encapsulated irinotecan and doxorubicin group and 
liposomal group demonstrated greater survival (p< 0.05) than the free drug at 
equivalent doses in this model (Figure 40).   
Finally, the percentage weight loss at nadir was used to evaluate the toxicity of 
the treatments (Corbett 2002).  The percentage weight change of the free doxorubicin: 
irinotecan combination was statistically different (p< 0.05) as compared to that of 
liposomal co-encapsulated irinotecan and doxorubicin group (Figure 41).  This could 
be due to the sequestering effect offered by liposome (Krishna, Webb et al. 2001), 
which results in reduced biological activity of the encapsulated drugs on the normal 
body tissues, thereby reducing adverse side effects and minimizing weight loss at 
nadir (Lee 2006).  The reduced exposure of drugs co-encapsulated in the liposomal 
formulation to body tissues was further confirmed when the dried spleen weight of 
different treatment group was tested (Figure 42).  The results of this study also 









SUMMARY DISCUSSION AND CONCLUSION 
5.1 Summary Discussion 
The two drugs, irinotecan and doxorubicin, have shown promising antitumor 
activity in ovarian cancer under clinical settings when used in combination near to 
their maximum tolerated dose (MTD) (Nishimura, Tsuda et al. 2007).  However, 
despite the benefits offered by these two drugs as drug cocktail, their use is restricted 
due to the complications arising from drug related toxicity, which could be due to the 
high doses of individual drug administered to the patients as part of MTD the 
approach. The shortcomings in this reported study led to three questions. First, is it 
always essential to make use of MTD approach so as to get maximum benefit out of 
drug combinations? Second, is it possible to overcome the drug related toxicity by co-
encapsulating the two drugs in a single drug carrier such as liposome? Third, will such 
co-encapsulated liposomal drug formulation be effective to produce the desired 
antitumor activity in ovarian cancer? With the help of results collected in the present 
study, we have attempted to answer the above queries, and these answers will be 
discussed in the following section. 
 First, it is not essential to use MTD approach in drug combination studies so 
as to get maximum benefit. In fact, it has been proven that the drugs when combined 
and dosed in specific drug: drug molar ratios provided maximum efficacy with 
minimal dose (Mayer, Harasym et al. 2006; Harasym, Tardi et al. 2007). This type of 
dosing is called ratiometric dosing, and is explained in detail under section 2.1. 
Although irinotecan and doxorubicin have been combined separately with various 
anticancer agents in a specific synergistic ratio (as discussed in section 4.1), no 
attempt has been made to identify the desired synergistic ratio in which these two 
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drugs can be combined and used to treat ovarian cancer.  Ours is the first systematic 
attempt to investigate the role of drug ratio-dependant synergy for doxorubicin: 
irinotecan combinations. The relationship between the doxorubicin: irinotecan ratio 
and synergy/antagonism was evaluated using the ovarian cancer cell lines; IGROV-1, 
OVCAR-3, and SKOV-3.  The results revealed 1:1 doxorubicin: irinotecan molar 
ratio as most synergistic in all the three ovarian cancer cell lines (section 4.1). 
Second, it is indeed possible to overcome the drug related toxicity by 
delivering the two drugs in a single drug carrier such as liposome (Mayer, Harasym et 
al. 2006; Lee 2006).  Besides, offering protection from the adverse effect of drugs to 
the body tissues, co-encapsulation of drugs into single liposome, also provides 
advantage of delivering the two drugs in vivo in synchronized manner.  In the present 
project, various parameters that affect liposome formulation co-encapsulating 
irinotecan and doxorubicin were studied in great detail.  Co-encapsulation of drugs 
into single liposome has been reported mainly using metal ion containing salts as 
hydration medium (Abraham, McKenzie et al. 2004; Taggar, Alnajim 2006; Ramsay 
Alnajim 2007; Li , Cui et al. 2008; Cui, Li et al. 2009; Tardi, Dos Santos 2009; Wong, 
Chiu et al. 2011).  However, there is no exclusive study that compares the use of 
citrate buffer (widely used buffer for liposome making) or ammonium sulpahte buffer 
(buffer used for preparation of commercially available doxorubicin liposome 
preparation) with that of metal ion containing salts in terms of their ability to co-
encapsulate the two drugs in single liposome. We compared five different types of 
hydration media (citrate, ammonium sulphate, ferrous sulphate, copper sulphate, 
manganese sulphate) in terms of their ability to co-encapsulate doxorubicin and 
irinotecan in single liposome.  In addition, the effect of ionophore (A23187) mediated 
pH gradient on co-encapsulation of doxorubicin and irinotecan in to liposome were 
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also investigated. The results revealed that mere pH gradient generated via citrate and 
ammonium sulphate was not sufficient to co-encapsulate the two drugs into the 
liposome with high efficiencies (section 4.2).  On the other hand, mere copper 
gradient and combination of metal ion gradient and ionophore mediated pH gradient 
using ferrous sulphate + A23187, copper sulphate + A23187, manganese sulphate + 
A23187 provided efficient co-encapsulation of doxorubicin and irinotecan into 
liposome (section 4.2).  Although copper sulphate +/- A23187 based liposomes have 
been previously reported to encapsulate mitoxantrone, irinotecan and topotecan as 
single agent formulations, these preparations have never been explored to co-
encapsulate two drugs in single liposome. Our attempt of co-encapsulation of 
irinotecan and doxorubicin using copper sulphate +/- A23187 based liposome is the 
first one.  Interestingly, the result also demonstrated that efficient co-encapsulation of 
these two drugs into copper sulphate liposome could be achieved even without 
ionophore A23187.  In another reported study, it has been stated that loading of 
irinotecan in copper sulphate - A23187 based liposome could be mainly due to 
irinotecan-copper complexation (Ramsay, Alnajim et al. 2006). If this proposed 
mechanism is true, then in the present study, the driving force for co-encapsulation of 
doxorubicin and irinotecan could be complexation between copper-irinotecan and 
copper-doxorubicin.  In order to confirm this possible mechanism of complexation, 
we investigated copper complexation with irinotecan/doxorubicin using computer 
modeling (section 4.2).  In addition, we also evaluated the effect of increase in 
intraliposomal concentration on drug loading. Both these studies led us to the 
conclusion that indeed complexation between copper and irinotecan/doxorubicin is 
the driving force for co-encapsulation of these two drugs into the liposome, further 
supporting the mechanism proposed by Ramsay et al.  In addition, this is the first 
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attempt where ferrous sulphate + A23187 have been used to hydrate liposome and 
subsequently co-encapsulate anticancer drugs in to the liposome.  Lastly, manganese 
sulphate + A23187 based liposome demonstrated efficient loading of irinotecan and 
doxorubicin into the liposome.  Manganese sulphate + A23187 based liposome have 
been previously reported to co-encapsulate doxorubicin and vincristine for treatment 
of breast cancer (Abraham, Mckenzie et al. 2004).  Also, it is noteworthy to realize 
that these hydration medium used were buffered in the acidic range (pH 3.5~4.0) and 
this pH range have been shown to preserve the active lactone form of irinotecan when 
encapsulated into liposome in presence of ionophore A23187 (Messerer, Ramsay et 
al. 2004; Tardi, Gallagher et al. 2007; Ramsay, Alnajim et al. 2008).  Moreover, 
preservation of irinotecan in its lactone form has shown to enhance therapeutic 
activity of the liposomal irinotecan formulations (Messerer, Ramsay et al. 2004; 
Ramsay, Alnajim et al. 2006; Ramsay, Alnajim et al. 2008) 
  In the recent past, use of liposome for co-encapsulation of two anticancer 
drugs have gained wide acceptance and is likely to become more common in the years 
to come.  In this view, the need of newer hydration media will be required to co-
encapsulate different kind of drug combinations.  We believe that this study on 
identification of suitable hydration media could provide the researchers working in the 
field of liposome technology with additional hydration media to work with. Besides 
efficient loading of drugs into the liposome, it is important that the drugs co-
encapsulated into the liposome are released in controlled and coordinate manner. 
Thus, we compared the release profile of those batches of liposome that demonstrated 
efficient drug loading. The results revealed that ferrous sulphate + A23187 based 
liposome failed to maintain the irinotecan: doxorubicin in desired 1:1 molar ratio 
(section 4.2).  In contrast, the copper sulphate +/- A23187 and manganese sulphate + 
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A23187 based liposomes coordinated the drug release and maintained the desired 1:1 
molar ratio.  The coordinate release of two drugs with liposome as drug delivery have 
been successfully demonstrated in the past as well using drug combination such as 
irinotecan with floxuridine (Tardi, Gallagher et al. 2007), doxorubicin with vincristine 
(Abraham, McKenzie et al. 2004), cytarbine with daunorubicin (Tardi, Harasym et al. 
2009) and fludarabine with mitoxantrone (Zhao, Wu et al. 2007).  The liposome that 
demonstrated desired release profile (copper sulphate +/- A23187 and manganese 
sulphate + A23187 based liposomes) were subjected to stability testing and the data 
suggested that manganese sulphate + A23187 liposomes possessed  superior stability 
profile when compared to copper sulphate +/- A23187 based liposome (section 4.2).  
The manganese sulphate + A23187 liposome preparation was found to be stable at 
4ºC for period of 24 weeks ; less than 15 % of drug loss was observed during the 
course of study and most importantly the ratio of two drugs was still maintained in 1:1 
molar ratio.  The enhanced stability of the drugs could be attributed to the presence of 
cholesterol in the formulation, which is known to reduce permeability of lipid bilayer 
and subsequent drug leakage from the liposomal preparation (Drummond, Meyer et 
al. 1999).  This is of great significance as drug stability is very much desired if this 
liposomal preparation needs to be further used under clinical settings, where normally 
the preparations are stored for weeks before actually being administered to the 
patients.  In addition, most of the liposomal preparations are freeze dried during 
storage and needs to be reconstituted before its actual use, which might be 
cumbersome and time consuming.  The liposomal preparations in the present study 
were found to be stable at 4ºC in its original injection (liquid) form and can be used as 
such during administration to the patients.  However, if this liposomal preparation is 
to be kept for more than 24 weeks, we would encourage freeze drying of the 
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preparation in order to avoid any potential degradation.  As manganese sulphate + 
A23187 based liposome was found to be superior in terms of drug loading, release 
properties and stability, this liposomal formulation was further characterized and 
developed based on various parameters discussed in section 4.2. The manganese 
sulphate + A23187 based liposomes showed effective drug loading at high lipid 
content and moreover the liposomal formulation was capable of encapsulating 10:1 
and 1:10 irinotecan: doxorubicin molar ratio.  Furthermore, these molar ratios were 
stably retained during the course of drug loading.  These results further confirm that 
this approach enables one to encapsulate drugs in different molar ratio to the same 
liposome with ratiometric control over drug loading.  In the previous reported studies, 
the co-encapsulation of two drugs into single liposome has been hydrated mainly 
using metal salt solution in the concentration range of 300 mM or less (Abraham, 
McKenzie et al. 2004; Taggar, Alnajim 2006; Ramsay Alnajim 2007).  There are no 
reported studies that have studied the influence of different concentration of metal salt 
solution on co-encapsulation of drugs into the liposome. Ours is the first attempt in 
this direction and we compared the effect of concentration of manganese sulphate, 
ranging from 150 mM to 750 mM on co-encapsulation of irinotecan and doxorubicin 
into the liposome.  A linear relationship was observed between increase in manganese 
sulphate concentration and co-encapsulation of irinotecan and doxorubicin (section 
4.2) and loading at high drug-to-lipid molar ratio of 0.9/1 was achieved successfully 
using 750 mM.  Drug loading at high drug-to-lipid molar ratio is of great significance 
for two reasons.  First, high pay load allows lower volume of injection volume so as 
to deliver the desired dose under preclinical as well as clinical setting.  Second, 
enhancement of drug retention has been reported with increase in drug-to-lipid molar 
ratio (Johnston, Cullis et al. 2008).  In addition, enhanced drug retention into liposome 
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and subsequent prolonged exposure of drugs to the tumor in vivo has been reported to 
increase the efficacy of liposomal preparation used in treatment of ovarian cancer 
(Patankar, Anantha et al. 2011).  Since high levels of metal ion concentration is used 
in order to achieve high drug-to-lipid molar ratio, it became imperative to determine 
the residual Mn2+ ion associated with liposomal preparation, as high levels of Mn2+ 
ions could lead to neurotoxicity (Dobson, Erikson et al. 2004).  Fortunately, the 
residual Mn2+ levels were well below the toxic levels, even for those prepared with 
750 mM manganese sulphate and thus pose no immediate threats of neurotoxicity. 
Cryo-TEM based images of liposomes containing doxorubicin, irinotecan, topotecan, 
vincristine, mitaxontrone as single agent have been reported previously. However, 
none of the study has reported images of co-encapsulated preparation and thus we 
carried out Cryo-TEM analysis of liposome formulation co-encapsulating irinotecan: 
doxorubicin and liposome formulation containing irinotecan or doxorubicin as single 
agent (section 4.2).  The Cryo-TEM images for liposome formulation co-
encapsulating irinotecan: doxorubicin exhibited a dense core without a defined 
structure.  From the formulation perspective, the liposomal formulation developed in 
the present study offered several advantages which include efficient co-encapsulation 
of drugs into synergistic drug: drug molar ratio, high drug loading capacity, desired 
release and stability properties, controlled and coordinated release of the two drugs. 
The fully developed and characterized manganese sulphate + A23187 liposome was 
further used for in vivo studies. 
Third, yes indeed the co-encapsulated liposome preparation could provide the 
desired pharmacokinetic properties and antitumor activity so as to treat ovarian 
cancer.  From a clinical perspective, this work presented in this thesis represents the 
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first attempt to explore the use of irinotecan and doxorubicin as drug combination in 
co-encapsulated liposome product for treatment of ovarian cancer.   
5.2 Conclusions 
In the present thesis, the overall objective was to develop effective treatment 
modalities to treat ovarian cancer, particularly recurrent type of ovarian cancer.  
Currently, either high dose chemotherapy (Ozols, Ostchega et al. 1985; Cagnoni and 
Shpall 1997; Toy and Rutherford 2001) or the combinations of various 
chemotherapeutic agents (Nishimura, Tsuda et al. 2007) are being employed to 
manage ovarian cancer.  However, these treatments have been shown to be either less 
effective or associated with drug related toxicities.  In this work, liposome co-
encapsulating doxorubicin and irinotecan in synergistic 1:1 ratio were developed. 
Synchronized release of two drugs in the desired 1:1 molar ratio was observed in vitro 
as well as in vivo.  Stability study demonstrated that developed liposome formulation 
was stable and retained the two drugs in 1:1 molar ratio for period of 24 weeks.  The 
efficacy study revealed that the co-encapsulated liposome formulation exhibited 
significant antitumor activity at two-thirds of the MTD of doxorubicin and one-tenth 
of the MTD of irinotecan as compared to the free drug combination with concomitant 
reduction in toxicities.  Therefore, it can be concluded that the developed liposomal 
formulation co-encapsulating doxorubicin and irinotecan is efficacious and has the 








 Chapter 6 
FUTURE DIRECTIONS 
Considering the fact that presently there are limited chemotherapeutics options 
available for the treatment of platinum refractory type of ovarian cancer and also 
taking into account the prevalence of ovarian cancer in Singapore and worldwide, the 
present study was focused on using irinotecan/doxorubicin combination for treatment 
of ovarian cancer.  However, the irinotecan/doxorubicin combination has 
demonstrated significant success in clinical and precilical testing for small cell lung 
cancer besides ovarian cancer (Morgensztern, Baggstrom et al. 2009; Xenidis, 
Vardakis et al. 2010).  Thus, the combination of irinotecan/doxorubicin could be 
tested using cell based assays to verify the ratio of these two drugs required to provide 
synergistic or at least additive effect in established small cell lung cancer cell line 
such NCI H69, H128, and N231.  Furthermore, the synergistic ratio that will be 
obtained from these screenings can be co-encapsulated into liposome which can be 
further tested in tumor bearing animal models. 
 The developed formulation in the present study consisted of DSPC and 
cholesterol, without any functionalized coatings as the onus of the project was not on 
target based therapy.  However, coating of liposomes with various ligands such as 
transferrin receptor and folate receptor might further enhance therapeutic efficacy. 
Folate-conjugated liposomes have demonstrated useful activity in treatment of ovarian 
cancer. Thus, the developed liposomal formulation in the present study could be 
conjugated with suitable ligand and whether it offers any added benefit effect could be 




The work in the present thesis has demonstrated that 1:1 molar ratio of 
irinotecan/doxorubicin provides synergistic activity against three different ovarian 
cancer cell lines.  However, the molecular mechanism responsible for the synergistic 
activity of this combination could be further explored for better understanding of the 
mode action of these two drugs as drug cocktail.  In addition, the cell lines used in the 
present study (IGROV-1, SKOV-3, and OVCAR-3) are representative of ovarian 
cancer and have been widely used to successfully demonstrate the effectiveness of 
various ovarian cancer treatments in vitro (cell based screenings) and in vivo (efficacy 
studies in xenografts).  However, use of primary cell lines (cells cultured directly from 
ovarian cancer patient) to confirm some of the key findings of the present study would 
be a great value addition, as it would more closely represent the actual human ovarian 
tumors in terms of its responsiveness to the treatment.   
Lastly, the present study has shown promising antitumor activity at two third 
dose of MTD of the doxorubicin and one tenth of that of irinotecan.  Moreover, we 
have encapsulated both these drugs into single liposome formulation and 
demonstrated the potential of this formulation with preliminary in vivo studies.  
Therefore, from clinical perspective, it would be good to conduct extensive preclinical 
trials using the formulation developed in the present study.   
We believe, the proposed novel liposomal preparation would help to improve 
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